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2Abstract
Objectives   This study examined nervous system effects and other health effects in tunnel
workers exposed to acrylamide and N-methylolacrylamide during tunnel work.
Methods  Symptoms and nerve conduction properties were recorded in 25 tunnel workers
exposed to acrylamide and N-methylolacrylamide during grouting operations, four and 16
months after the cessation of exposure. Visual evoked response (VEP) and electroretinography
(ERG) were performed 16 months post exposure. Hemoglobin adducts of acrylamide were
measured and qualitative exposure indices were developed.  Fifty unexposed tunnel workers
served as referents. Chromosome aberrations and the distribution of Glutathion S transferase
(GST) genotypes (M and T) were also examined in the 25 exposed workers, and were
compared to 25 age and smoking matched referents.
Results  The exposed workers reported an increased prevalence of symptoms during grouting
work compared to the examination after 16 months. A statistically significant reduction in
mean sensory nerve conduction velocity (NCV) in the ulnar nerve was observed 4 months post
exposure when compared to the reference group (52.3 vs. 58.9 m/s, p=0.001), and mean ulnar
distal delay was prolonged (3.1 vs 2.5ms, p=0.001).  Both measures were significantly
improved when measured one year later.   By correlating outcome measurements with the
qualitative exposure indices of the individual workers, exposure-related improvements from
four to 16 months post exposure were observed both in the median nerve (motor and sensory
NCV and F-response) and the ulnar nerve (sensory NCV, F-response).  A significant reversible
reduction in the mean sensory amplitude in the median nerve was also observed, while sensory
amplitudes in the sural nerve were significantly reduced after 16 months. The amplitudes in the
electroretinography on photoptic (30 Hz) stimulation were significantly lower in the exposed
subjects compared to the referents.  There were no clear differences in the neurophysiological
outcome parameters related to GST genotypes M and T.  Chromosome examinations showed
no significant differences between the 25 exposed subjects and 25 of the referents for
chromosome aberrations, chromatid breaks, chromosome breaks and chromosome gaps.  A
significant increase in chromatid gaps was observed in the exposed subjects, but no exposure-
response relationship could be found.  Subjects with GSTM1-/GSTT1 genotype had slightly
higher frequencies of all effect parameters compared to referents with the same genotype.
Conclusion  The results indicate slight effects on the peripheral nervous system in tunnel workers
related to exposure to N-methylolacrylamide and acrylamide during grouting operations. Apart from a
3possible delayed axonal effect on sensory fibres in the sural nerve, the effects seemed largely to have
been reversible, with normalisation 16 months post exposure. A possible slight change in the ERG
suggests subclinical effects on photoreceptors (cones) in the central part of the retina. The pattern of
the chromosome results may indicate a possible slight genotoxic effect.
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51. INTRODUCTION
Monomeric acrylamide is neurotoxic, probably carcinogenic to humans, and may have
reproductive effects on animals ((WHO, 1985; IARC, 1994).  Thus, occupational exposure to
acylamide may present a hazard to the workers, primarily by affecting the nervous system,
including both peripheral and central nervous effects (WHO 1985). Acrylamide-containing
grouts have been used in tunnel construction work for several decades, in order to prevent
water leakage into the tunnel. Due to the toxic properties of acrylamide, several other grouts
have been  developed, among them one  based on the less toxic N-methylolacrylamide (NMA).
During 1995-1997, 340 tons of an NMA-based grouting agent, Rhoca-Gil (Sipro-Gel) was used
for injection in Romeriksporten, a 14 kilometer long railway tunnel from the city of Oslo to the
new Gardermoen airport located north of Oslo. Reports of adverse effects from use of the same
grouting agent from another tunnel project in Hallandsåsen in Sweden appeared in the
Norwegian press during August 1997 (Hagmar et al., 2001).  Shortly after, several Norwegian
tunnel workers also complained of symptoms compatible with acrylamide effects. During the
autumn of 1997, all workers engaged in the injection work in Romeriksporten were invited to a
health examination at the Occupational Health Services (OHS survey) of the construction
company. Subjects with suspected signs and symptoms were referred to further examinations
on an individual basis.
The National Institute of Occupational Health (NIOH) initiated an epidemiological study to
further examine the possible relationship between exposure to acrylamide-containing grouting
solution and neurological symptoms and signs in the tunnel workers. Exposure assessment was
partly performed qualitatively using detailed interviews and questionnaires, and quantitatively
by measurements of hemoglobin adducts to acrylamide, a biomarker for recent exposure.
Neurophysiological examinations, including neurography, visual evoked responses and
electroretinography, were performed. We have also examined chromosome aberrations in
exposed groups and individual factors related to biotransformation and detoxification of
acrylamide (GST genotypes).
This report presents a summary of the OHS survey (Brudal et al., 1998), and reports the results
from the NIOH follow-up study of 25 tunnel workers from Romeriksporten.  Thus, the focus in
this report is on the possible acute effects in the exposed tunnel workers, together with possible
6reversibility of effects one year later, when the group was re-examined.  Results from this
project has also been published elsewhere (Kjuus et al., 1999, Kjuus et al., 2001, Kjuus et al.,
2002).
Acrylamide-containing grouts have been used in many major tunnel projects in Norway during
the early 90’s. To our knowledge, there has been no report of adverse health effects.  However,
no systematic investigations had been undertaken to explore this relationship.  We therefore
initiated another epidemiological study, with the aim of examining if there could be any
persistent effects of  acrylamide exposure several years after the cessation of exposure to
acylamide-containing grouts. That study, which also includes an examination of
neuropsychological function, colour vision and vision fields, will be reported separately
(Goffeng et al., 2000, Goffeng et al., 2002, in preparation).
2.  BACKGROUND
2.1  Acrylamide and N-methylolacrylamide in grouts
Acrylamide grouts were introduced in the 1950’s.  They quickly obtained a major share of the
market, owing to their low cost and superior performance properties.  In the USA, the
production of acrylamide grout ceased in the late 1970’s owing to the producers’ concern for its
potential risk to humans.  However, in 1989 acrylamide grouts still accounted for more than
40% of the grout use in USA.
The grout is typically injected in and around concrete, rock and soil to increase the absolute
strength of the mass and to restrict the water flow through a structure or the grouted area.   The
majority of its use has been in sewer rehabilitation, during sewage lining repair or manhole
sealing.  Other uses include structural water control, e.g. during tunnel construction, and other
geotechnical applications.  These operations involve manual injection techniques.
In general, acrylamide grouts consist of a 19:1 mixture of acrylamide and crosslinking agent.
When the grout is prepared for use, water and small amounts of catalysts, activators or
accelerators and inhibitors are added.  When the acrylamide grout polymerises, it solidifies into
a stiff gel which is impervious to water.  In the gel form, the grout contains less than 0.05%
free acrylamide. An assessment of chemical grouting agents, including acrylamide, was
performed by NIOH in 1982 (Bye and Lenvik,1982).
7Of the less toxic grouts that were developed, one was based on N-methylolacrylamide (NMA).
NMA is produced from acrylamide and formaldehyde, in aqueous solution:
Acrylamide + Formaldehyde  ↔  N-Methylolacrylamide.
The reaction is slightly reversible, where NMA is hydrolysed back to acrylamide.  The extent
to which this happens in practice is not known and is dependent on the environmental
conditions. NMA may also be partly transformed to acrylamide at high pH and when sodium
silicate is added.  At temperatures below 5°C polymerisation of the monomer may be
considerably delayed in relation to the gelling of the silicate. Consequently the grout will not
adhere perfectly adhered to the fissures and may leak out again.  Thus, exposure to the mixed,
but not yet polymerised product may occur.
2.2  Acrylamide – kinetics and metabolism
Acrylamide is readily absorbed via all routes of administration. Thus, it has been reported that
acrylamide induces neurotoxic effects in many animal species following absorption via the
respiratory, dermal and oral routes (WHO, 1985). The development of neurotoxicity is
independent of the route of absorption, probably because it is distributed to all body fluids.
Once absorbed, acrylamide is rapidly distributed throughout the body, metabolised and
excreted. After oral administration in rats of 1-100mg/kg of acrylamide, 65-80% of the dose
was excreted after seven days, of which 90-95% in the urine (Sipes and Carter, 1981).  Rather
surprisingly, the highest concentration has been found not in the nerves, but in red blood cells.
After intravenous injection, 10% of the administered dose remained relatively constant in the
blood for one week.  By contrast, the lowest concentration was found in nervous tissue (less
than 1% of the administered dose was found in brain, spinal cord and sciatic nerve after i.v.
administration). Acrylamide in relatively large quantities was found in areas having high blood
flow, such as muscle, skin, liver and small intestine. Acrylamide is excreted primarily as
metabolites (>90%), while less than 2% is excreted as the parent compound in the urine. (Sipes
and Carter, 1981). Acrylamide is primarily conjugated with gluthathion and is excreted as
mercapturic acid (n-acetyl-cystein conjugate). A minor proportion is oxidised to glycidamide
through the cytochrome P-450 system. Glycidamide has high reactivity, particulary against free
8thiol-groups, and is excreted in conjugated forms. The elimination curve for acrylamide follows
a biphasic, first order kinetics pattern.  The half-life for acrylamide (T1/2) is approximately 2
hours in blood and 5 hours in tissue.  The terminal T1/2 for most tissues was 6-8 days, while it
was found to be significantly longer for the spinal cord (approximately 24 days) (Tilson, 1981).
2.3  Nervous system effects of acrylamide
The variety of symptoms described in cases of acrylamide poisoning suggest involvement of
both the central and peripheral nervous system, together with the autonomic nervous system.
The reported symptoms include irritation of skin and mucous membranes, with peeling of the
skin of the hands and feet, muscular weakness, paresthesia, numbness in hands, feet, arms and
legs, and unsteadiness with difficulties in walking and standing (WHO, 1985). Other symptoms
reported are unusual fatigue and sleepiness, dizziness and memory difficulties. Vegetative
symptoms, such as excessive sweating of the hands and feet (Takahasi et al., 1971; Kesson et
al., 1977), and micturation and defaecation difficulties (Garland and Patterson, 1967) have also
been reported.
The clinical signs found in cases of poisoning are consistent with the reported symptoms. Thus,
contact dermatitis, with blueness and sometimes redness of hands and feet (Auld and Bedwell,
1967), loss of tendon reflexes, impairment of sensation, and muscular wasting have been
observed (Takahasi et al., 1971; Kesson et al., 1977)
Altogether, since the first report on acrylamide poisoning in man was presented in 1953
(Kuperman, 1957), more than 150 cases has been presented, mainly related to the primary
production of acrylamide from acrylonitrile (Kuperman, 1957; Fujita et al., 1960; Morviller,
1969), or to the polymerisation of acrylamide to polyacrylamide (Auld and Bedwell, 1967;
Garland and Patterson, 1967).  The first report on acrylamide-related health effects in
construction workers related to waterproofing was presented in France in 1970 (Graveleau et
al., 1970).   Later reports in tunnel workers relate mainly to the polymerisation of acrylamide in
grouting operations (Kesson et al., 1977; Mapp et al., 1977). In most cases, the symptoms and
signs have been shown to be reversible, with full restitution 2-12 months after the cessation of
exposure (WHO, 1985). However, in severe intoxications, symptoms have persisted for several
years (Myers and Mahun, 1991).
9The grouts used by the workers in the aforementioned studies seem mainly to have been based
on pure acrylamide, although in one study they are based on N-Methylacrylamide and
Methylen-bis-acrylamide (Graveleau et al., 1970). Thus, the Swedish study (Hagmar et al.,
2001) and the present study are the first to examine neurological effects in workers exposed to
grouts based on N-methylolacrylamide.
2.4 Mechanisms for acrylamide-induced neurotoxicity
 Analogous of acrylamide with structural modifications have been tested for the potential to
induce neurotoxicity in animals. Substitutions at the amide nitrogen resulted in a decreased
neurotoxic potential and saturation of the double bond abolished neurotoxicity (Edwards, 1975;
Hashimoto, 1981). Covalent binding of acrylamide to central nervous system proteins may play
an important role in the toxicity, resulting in inhibition of a number of enzymes and essential
compounds (Carlson and Weaver, 1985). The unsaturated double bond of acrylamide is
relatively reactive towards free thiol groups in glutathione (GSH) and cystein. Depletion of
GSH in mice brain enhanced the neurotoxicity effects. GSH may play an important role in the
detoxification of acrylamide in the nervous system (Shivakumar and Ravindranath, 1992).
Although some DNA binding has been shown in vitro, acrylamide only demonstrated weak
activity (Dearfield et al., 1995). This in contrast to its epoxide metabolite glycidamide, which
has been positive in the Salmonella mutation assay. Typical DNA adducts from acrylamide
exposure also indicate the involvement of the epoxide in genotoxicity (Dearfield et al., 1995).
The glycidamide may also have neurotoxic effects.
Two principally different types of pathological changes may occur in peripheral nerves.  In
segmental demyelination, there is a patchy breakdown of myelin affecting individual internodal
segments, while the axis cylinders remain in continuity.  The primary neurophysiological
finding will be a significant reduction of nerve conduction velocities due to myelin damage.
This neuropathy has been found after exposure to lead, triethyltin and isonicotinic acid
hydracide (Norton, 1986).   In axonal degeneration, on the other hand, biopsies may show
axonal degeneration of nerve fibres, a reduction of large diameter nerve fibres and /or the
accumulation of neurofilaments in the axon. The conduction velocities of motor and sensory
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fibers are often normal at the electrophysiological examination.  However, the amplitude of
sensory and motor nerve action potentials is often reduced.
Although extensively studied in animal models, the mechanisms by which acrylamide exerts its
neurotoxic effect is still not clear (Miller and Spencer, 1985; Tilson, 1981; Smith and Oehme
1991). What is clear, however, is that neurons both in the CNS and PNS are targets for the
insult from acrylamide.   Acrylamide is capable of producing axonopathy by transsection of
neurons, which leads to the degeneration of that proportion of the axon which is separated
anatomically from the nerve cell body (Smith and Oehme, 1991).
Thus, the morphological effects of acrylamide on peripheral nerves are primarily axonal
degeneration with secondary demyelination, predominantly in the distal part of long nerves
with diameters of 8-16 um (Smith and Oehme, 1991). Sensory fibres are first affected, followed
by degeneration of motor fibres and long axons of the spinal cord, leading to a reduction in the
number of large diameter fibres. Accordingly, sensory nerve action potential amplitudes have
been reported to be the most sensitive indicator of acrylamide intoxication (Igishu et al). The
accumulation of neurofilaments and enlarged mitochondria lead to significant swelling in
terminal axons of the PNS and the boutons terminaux in the CNS. Degenerative changes also
occur in the autonomic nerve fibres.
An important difference exists, however, in the outcome of axonal degeneration in the CNS
compared to that in the PNS: peripheral axons can regenerate whereas central axons cannot
(Norton, 1986).  This implies that recovery (partial or complete) can occur after axonal
degeneration in the PNS, whereas effects on the CNS tend to be irreversible.
Several investigations have been conducted concerning the possible effects of acrylamide on
axonal transport. Peripheral sensory nerves are bipolar neurons, with a peripheral axon that
may extend the entire length of a limb and a central axon that projects towards the brain.   The
axon is capable of transferring electrically encoded information over long distances (up to two
metres). Because the axoplasm is unable to synthesise lipids or proteins, the axon is dependent
solely upon its neuronal cell body (perikaryon) which is located in the dorsal root ganglion.
The perikaryon is the main site for protein and lipid synthesis, but the axon is capable of
modifying them by phosphorylation and other mechanisms (Smith and Oehme, 1991).
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The main function of the anterograde transport (down the axon) is to move various structural
proteins (neurofilament triplet proteins, tubulin, actin), enzymes ( glycolytic enzymes,
dopamine-β-hydroxylase, acetylcholinesterase) and substance P and neurotransmitters
(acetylcholine, norepinephrine) distally along the axon. Previous studies indicate that
acrylamide interferes with the rapid anterograde transport of substances (down the axon), but
may not significantly affect the slow transport system (Tilson, 1981). In contrast, several later
studies have found a reduction in the slow anterograde transport (Smith and Oehme,1991).  A
Danish study suggests that although acrylamide may play a role in the slow anterograde
transport late in the neuropathic process, neither fast nor slow components are involved in the
initial pathological events in the distal axons (Sidenius and Jacobsen, 1981).
The purpose of the retrograde axonal transport is to transfer axoplasmic constituents for
reprocessing in the perikaryon.  The fast retrograde system transports a variety of substances
(e.g. acetylcholinesterase, adrenergic granules, lysosomes) at a rate of 1.5-2.5 cm a day. The
slow retrograde axoplasmic system transports a single protein, probably albumin, at a rate of 3-
6 mm a day.  Acrylamide may initiate subtle changes in the structural lattice of the axon,
causing retrograde transport to decrease and eventually stop (Smith and Oehme, 1991, Miller
and Spencer, 1984).  This effect is dose dependent and precedes the development of clinical
signs of neuropathy.  Sensory neurons have been shown to be more sensitive to acrylamide than
motor neurons.
It has also been shown that acrylamide may penetrate the neuron at the neuromuscular junction
by pinocytosis and bind to sulfhydryl groups in the axon of the nerve, resulting in disassembly
of microtubules in the axon and the disruption of retrograde transport (Smith and Oehme,
1991).  This mechanism may be potentially relevant to dermal exposure, implying a potential
direct toxic effect on the nerve at the neuromuscular junction, in addition to the systemic effect.
2.5  Neurophysiologic effects of acrylamide exposure.
Fullerton and Barnes presented in 1966 an electrophysiological and histological study in
chronically poisoned rats, which were given repeated oral doses of 25 to 100mg/kg at various
intervals. In the animals with severe clinical abnormalities, motor nerve conduction velocity
was reduced by about 20% (from 55m/s to 44 m/s), gradually developing from 6 to 12 weeks
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after the start of exposure (Fullerton and Barnes, 1966). Full recovery in NCV was observed
five to nine months after the cessation of exposure. Histologically, degeneration of axis
cylinders and myelin sheaths was found in the peripheral nerves, affecting predominantly the
distal parts of the longest fibers. Similar findings have been reported in other species (WHO,
1985; Tilson 1981; Smith and Oehme, 1991).
Hopkins and Gilliatt examined nerve conduction velocities in seven adult baboons intoxicated
by acryamide (Hopkins and Gilliatt, 1971).  In animals given 10-15 mg/kg/day, the gradual
development of a peripheral neuropathy was accompanied by a decline in amplitudes, which
were correlated with a 34-49% gradual fall in conduction velocity. In the most severely
affected baboon, partial recovery (to 80% of normal values) was seen 21 months post exposure.
Histological examination showed degeneration of the peripheral nerves with little
demyelination, suggesting that the reduced conduction velocities were most likely due to the
selective loss of large-diameter fibres and not to paranodal demyelination.
With regard to studies in humans, Fullerton performed electrophysiological studies of
peripheral nerves in three patients who had developed peripheral neuropathy and ataxia after
exposure to acrylamide during their work.  They had been exposed for 4 weeks, 6 weeks and 18
months respectively before the onset of symptoms, and the examination was performed 6, 8 and
2.5 months after cessation of exposure. Motor NCV was normal or slightly reduced, except in
one nerve (23.8 m/s in lateral popliteal nerve). Muscle response to nerve stimulation was
dispersed, potentials with markedly prolonged distal latencies were found, and sensory nerve
action potentials were reduced in amplitude or absent. The authors suggest that the slow
conduction was due to degeneration followed by regeneration of the distal part of the fibres.  In
15 workers handling acrylamide for 1-8 years and with varying signs of peripheral neuropathy,
the action potentials were greatly reduced while conduction velocity was not greatly affected.
Nerve conduction velocities were studied in 69chinese workers producing acrylamide. No
differences in NCV were observed when compared to a reference group, except for a slight
reduction in motor NCV in the peroneal nerve. In 27 subjects with neurological signs, the
sensory action potentials of the median, ulnar and sural nerves were decreased significantly
compared to those of the reference group (He et al., 1989).
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Acrylamide has also been shown to affect the visual system. Axonal swellings in the lateral
geniculate and superior colliculus have been described in intoxicated rats and cats (Schaumberg
and Spencer, 1979; Canavagh, 1982), and visual evoked response abnormalities have been re-
ported in rats (Boyes et al., 1980). A variety of pathological effects has been shown in the visu-
al system of macaque monkeys (Merigen et al., 1985). Also, there have been reported visual
effects in some of the human case histories (Mapp et al., 1977, Myers et al., 1991).
As previously described (Section 2.4) glutathione has a protective effect on the occurrence of
acrylamide-induced nerve damage. Acrylamide is conjugated to glutathione by glutation S-
transferases (GST’s). Glutation S-transferases occur in 4 different families, but the contribution
of the particular GST’s to the detoxification of acrylamide is unknown. In the Norwegian
population, about 50% lack GST M1 activity, and 15% lack GST T1 activity. One hypothesis
would be that subjects will have a different susceptibility to acrylamide-related nervous system
effects and genotoxic effects dependent on their efficiency to detoxify acrylamide compounds
via glutation conjugation.
2.6  Toxicology of N-methylolacrylamide.
The toxicological data on N-methylolacrylamide (synonyms: N-(hydroxymethyl)acrylamide,
N-(hydroxymethyl)2-propenamide, N-Metanolacrylamid, Monomethylolacrylamide)
are more limited than for acrylamide. There is no information on the uptake from skin or the
gastrointestinal tract. NMA is rapidly distributed in all body fluids after intravenous injection.
T1/2 in the blood is ca. 1.5. hours in rats. From available data, the toxicodymanics are
comparable to that of acrylamide, but with a reduced potential for neurotoxic damage and
carcinogenic development (Smith and Oehme, 1991; IARC, 1994; Ahlbom et al., 1998). In
animal experiments, the neurotoxic potential of NMA has been reported to be 20-30% of
acrylamide (IARC, 1994).  The carcinogenic potential of NMA has been estimated to 10 (rat)
and 100 (mice) times lower than for acrylamide.
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3.  THE ROMERIKSPORTEN TUNNEL PROJECT
A new airport for Eastern Norway was built at Gardermoen, 50 kilometers north of Oslo during
1995-98. A high speed railway between Oslo and Gardermoen was constructed, including a
13.8 km tunnel, Romeriksporten, from Etterstad in Oslo to Stalsberg in the district of Skedsmo.
Water leakage into the tunnel became a problem due to unstable rock structures in the tunnel
area.  This led also to an increasing environmental and public problem as several of the small
lakes in the area were involuntarily drained during the construction work.   In addition, there
were also discussions on the instability of house foundations in one of the suburbs, due to the
type of construction and the possible reduction in the ground water level. Thus, in addition to
the problems of water leaking into the tunnel, environmental issues were even more highlighted
and all tunnel work was stopped for a period.  Several traditional methods for stopping the
water leakage were used, primarily with cement, but other injection agents, based on
polyurethan (TACCS) and acrylate gel (Meyco MP 307) were also used in relatively large
quantities (125 000 and 57 000 kg respectively).
During September 1995 to August 1997 340 000 kg of Rhoca-Gil was used for injection in
Romeriksporten. In traditional use grouting agents are injected into wholes drilled in all
directions in the rock due to be blasted, which will normally prevent water leakage into the
excavated tunnel.  However, owing to the unexpected water leakages, the grouts were also
injected into fissures wich leaked water after blasting.  Thus, the normal polymerisation of the
gel was incomplete and was disturbed by the water leakage.
During August 1997, the Norwegian press reported adverse effects on the environment, cattle
and humans related to the use of 1340 tons of Rhoca Gil during a short period (6-8 weeks) in a
tunnel project in Hallandsåsen in Sweden.  Fish died, cows were intoxicated after drinking the
contaminated water, and the tunnel workers reported health effects compatible with effects
earlier described for acrylamide intoxication. These observations led to a comprehensive
examination, both in the environment and in the tunnel workers and the public living near
potentially polluted water sources (Edling et al., 1998; Hagmar et al., 2001).
At this time it was revealed that the grouting agents used in Romeriksporten also contained
acrylamide, an information which owing to incomplete labelling of the product was not known
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to the workers. Several of the workers interviewed in the press reported health complaints
which they related to their work.  Thus, the Occupational Health Service of the construction
company in charge of the project initiated a health survey of the tunnel workers.
3.1  Exposure conditions in Romeriksporten
The actual grout used in Norwegian tunnels (Rhoca-Gil 110-25 or SiproGel) was an NMA-
based grout based on two solutions.  Solution 1 consisted of 26-29%  NMA, 0.02-0.03% of the
cross linker Methylene-bis-acrylamide, 12-17% Methylic diesters (catalyst), small amounts of
other catalysts and stabilizers, together with impurities and water. According to the declaration
of content, Solution 1 also contained up to 1.5% acrylamide.  Later information from the
producer stated 2.5-5% (average 4% ) acrylamide in Solution 1, while analyses on different
batches from Hallandsåsen showed acrylamide concentrations between 4.0-5.4%, and NMA
concentrations between 29 and 31% (Hagmar et al.,2001). When ready-mixed, the grout
consisted of 3.75 parts of water. 0.125 parts Solution 1 and 0.125 parts Solution 2.  Initially,
Solution 1 and 2 were delivered in 30 L cans which were manually emptied into an open
mixing vessel and manually stirred. During the construction period, automatic pumping of the
two solutions was introduced, but the mixing was performed manually.  The not yet
polymerised mixture was then pumped into the rock in a closed system, through an injector gun
either as a preventive measure or to stop an actual water leakage in the tunnel.
When the injecton was finished at one location, the injection gun was moved to other drilled
holes or fissures.  After injection, the equipment was cleaned and sometimes repaired by the
operators.  The normal working hours in the tunnel were 12 hours per day for one week, then
one week off.  However, owing to the special problems with the water leakage, the injection
work often lasted until the leakage was under control.  This often led to very long working
hours, and some workers reported continuous work up to 24 hours in order to finish a job.
Worker exposures occurred during grout mixing, injection, equipment disassembly and clean
up. The main exposure occurred when mixing and pumping the grouting solution, and the
following drilling of holes in the wall when the grouting solution was injected.  Frequently, the
grouting solution splashed back at the worker, resulting in his clothing being covered with the
acrylamide-containing solution. In addition, workers often report «showers» of leaking water
contaminated with acrylamide.  Dermal absorption could then take place directly through the
skin on the neck or on the hands, or through wet clothes all over the body.
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The production volumes used in the different time periods and in the various parts of the tunnel
are shown in Figure 1 (page 22).   The figure shows that the major part of the Rhoca Gil grout
was increasingly used in the late construction period in the Gardermoen end of the tunnel.
Furthermore, both the available water samples for measurements of acrylamide in tunnel water
and the blood samples for adduct analyses were taken after the injection period had come to a
halt.
3.2  Initial OHS survey
All subjects who were involved in the injection work during the actual two-year period were
offered a health examination by the Occupational Health Services of the construction company
(SRG, (Scandinavian Rock Group ANS)).  The examinations were not compulsory, but all 73
injection workers from the company met for the examination during the period 20th October
1997 – 15th January 1998. Their average age was 40 years, with an average of 14.0 years of
tunnel work (range: 2.5-31.0 years).  Forty-three subjects were daily smokers , 10 had quit
smoking and 20 subjects were never smokers. They were all male, and had been working for
the company for 2.5 years on average.  Other workers with potential exposure to contaminated
tunnel water were also offered health examinations on an individual basis. The results from the
OHS survey have been presented in a separate report (Brudal, 1998), but will be summarized
here in short.
The health examination consisted of a semi-structured interview about the worker’s previous
work, tunnel experience and detailed information on his present injection work, work practices
and the use of personal preventive devices.  Information was obtained about present and
previous diseases, and in particular present symptoms from the nervous system, skin and
respiratory system.  A clinical examination was performed, including lung function
measurements (Forced Vital Capacity (FVC),  Forced Expiratory Volume in one second
(FEV1),  FEV1/FVC%,  and Peak Expiratory Flow (PEF), laboratory tests (Hb, Sed.rate, Urin
test) and a blood test for the later analysis of hemoglobin adducts to acrylamide in selected
groups.
All subjects with skin complaints which had started or became aggravated during the tunnel
work were referred to a dermatologist for further examination (Dr. Morten Sandberg, Oslo).
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They were tested with standard European epicutaneous tests for allergy to acrylamide i 0.1%
and 0.05% concentrations and to Rhoca Gil in 0.2-0.1% and 0.05%. Subjects with lung
complaints or reduced lung function (FVC or FEV1 < 80% of expected value, or FEV1/FVC <
75%) were referred to a lung specialist (Dr. Kurt Myhre, Dept. of Occupational and
Environmental Medicine, Ullevål Hospital).  Traditional spirometry, together with diffusion
capacity for CO, TLCO were performed.  A chest x-ray was taken of all the subjects.  Subjects
with symptoms and signs from the nervous system were referred to measurement of nerve
conduction properties (Dr. Mona Skard Heier, Dept. of Clinical Neurophysiology, Ullevål
Hospital).  The latter examinations were coordinated with the NIOH follow up study.
Altogether, 15 of the 73 subjects reported symptoms related to injection work with Rhoca Gil.
The symptoms were burning, itching, various types of eczema and peeling of skin. At the time
of examination, 13 subjects still reported symptoms, and 11 had clinical signs of skin affection.
In 10 subjects examined by the dermatologist, one had a specific contact allergy to acrylamide,
and he had also had skin reactions in connection with previous acrylamide contact in earlier
tunnel work.  Three subjects had non-allergic irritative contact eczema.  At the time of the
specialist examination, only two subjects had very modest skin changes.  There were no signs
of skin involvement in the remaining workers.
None of the 73 subjects reported acute respiratory symptoms during injection work. Some
reported an unpleasant smell when mixing the solutions.  However, they all reported work with
other injection agents, of which several have been reported to be irritative to the respiratory
system, e.g. the isocyanate-based TACCS.   According to the above-mentioned criteria, 41
subjects were referred to the lung specialist.  Among these, 15 subjects received a diagnosis of
chronic bronchitis (87% were smokers), and seven subjects were diagnosed as having chronic
obstructive lung disease (all were smokers).  The neurophysiological results are included in the
NIOH follow up study.
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4.  NIOH FOLLOW-UP STUDY
The follow-up study was designed as two cross-sectional examinations of subjects with recent
exposure to NMA-based grouts during tunnel work.  One main challenge was to identify
relevantly exposed subjects and to examine them as soon as possible after the cessation of the
injection work. Owing to the reports on possible health effects in Swedish tunnel workers, the
injection of Rhoca Gil in Romeriksporten was stopped 25th August 1997.  The first
examination was performed during October 1997-February 1998, i.e. on average four months
after the injection work was stopped.  The examinations were repeated one year later.
4.1  Aim of the study
The main aim of the study was to examine possible neurological effects and indications of
possible genotoxic effects of acrylamide exposure in tunnel workers.
More specifically, the aims were to:
- study symptoms and clinical signs of acrylamide effects in tunnel workers recently exposed to
Rhoca-Gil.
- determine levels of hemoglobin adducts to acrylamide in tunnel workers recently exposed to
Rhoca-Gil.
- examine nerve conduction velocities in tunnel workers with recent exposure to Rhoca-Gil.
-  explore the possible reversibility of  neurophysiological effects in Rhoca-Gil exposed tunnel
workers by re-examination of the workers after one year.
- examine possible visual effects of acrylamide exposure, by recording visual evoked response
(VER) and electroretinography (ERG).
 - study possible chromosome aberrations in subjects with recent exposure to Rhoca-Gil.
-  examine whether individual characteristics of the glutathione conjugation metabolism (GST
genotypes) might affect the susceptibility to possible aberrant effects of acrylamide.
4.2  Methods
4.2.1 Material
The study base consisted of the 73 exposed tunnel workers identified as those workers who had
taken part in injection work during the tunnel construction.  Thus, all 73 had been exposed to
acylamide-containing grouting solution (Rhoca-Gil) during work in Romeriksporten from
September 1995 to August 1997 and all participated in the OHS survey. Based on the
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information given at the interview and in the questionnaire at the OHS survey, and several
meetings with groups of the workers, the workers’ safety representatives, the health and
environmental chief officer at the plant and the occupational physician who had interviewed the
workers, we identified the workers with the highest and most relevant exposures. Thus, the 25
most heavily exposed workers among the 73 participants in the health survey of all tunnel
workers during autumn 1997 were selected for further study.  All workers gave written
informed consent to participate in the study. Altogether, 24 exposed subjects were included in
the analyses of symptoms and neurophysiologic measurements, as one worker was excluded
owing to diabetes.
In another study, we have examined the possible irreversible health effects related to the
previous exposure to acrylamide-containing grout in tunnel work in 50 exposed tunnel workers
and 50 referents recruited from tunnel workers in the same companies who were unexposed to
acrylamide-containing grouts (Goffeng et al., 2000). The latter group also served as referents
for  the index population in the present study.  In the chromosome studies, all 25 subjects were
included, and compared to a subsample of 25 age and smoking-matched referents from the
same reference group.
The 24  exposed workers were on average 43.1 (standard deviation, SD=8.6) years old (range
31-62), compared to 43.9 years (SD=9.6) in the 50 referents (range 23-60) . The exposed group
had been doing tunnel construction or other construction work for 19.3 (7.8) years compared to
20.4 (10.2) years in the referents. However, the exposed group had been involved in direct
tunnel work much longer than the reference group (14.8 (SD=8.3) vs. 3.8 (SD=4.0) years).
The distribution of some life style factors (smoking, alcohol consumption), and some other
relevant exposure factors are presented in table 1. No major differences in exposure to these
factors were observed between the two groups.  In the smokers, the exposed subjects had
smoked on average 12.8 cig./d, compared to 15.3 cig./d in the referents. The exposed workers
had worked with vibrating tools for 6.0 (SD:5.5) years, compared to 7.9 (SD:8.5) years in the
referents. The estimated annual alcohol consumption was slightly higher in the exposed
subjects.
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Table 1.  Background factors and other exposures reported by the
exposed group (n=24) and referents (n=50)
Exposed Referents
Age (years) Mean 43.1 43.9
Range 31-62 23-60
SD   8.6   9.6
Years in construction work   Mean 19.3 20.4
           SD   7.8 10.2
Present smokers (%) 45.8   50.0
Mean no. of cigarettes 12.8 15.3
Alcohol,  >5 L/year (%) 33.3 24.0
Work with solvents (%) 47.8 61.2 a
Previous lead exposure (%)  9.5   16.0
Vibrating hand tools (%)              100.0 91.9a
No. of years (Mean)              6.0   7.9
Vibration, whole-body (%)            34.8   50.0
 a n=49
During the period October 1997 to February 1998 all the exposed subjects were examined at
the NIOH and at the Department of Clinical Neurophysiology at Ullevål Hospital, Oslo,
preferably on the same day.  The workers received an additional questionnaire asking for more
detailed information on exposure, together with information on symptoms during injection
work and present symptoms (see Appendix 1).  The questionnaire was self-administered, and
followed by a short interview by one of the physicians in the project (VS or HK). New blood
samples were taken for the analyses of  gluthation S-transferase genotypes and chromosome
abberations.
Although the workers experienced exposure to Rhoca-Gil from unpolymerised acrylamide/-
NMA and contaminated tunnnel water during September-October 1997, the most relevant
exposure came to a halt when the injection work was stopped 25th August.  The NIOH exami-
nations were performed during October 97 – February 98, thus on average 4 months «post
exposure».
In order to study the possible reversibility of neurophysiological effects in Rhoca-Gil exposed
tunnel workers, they were re-examined after one year. Thus, the 24 workers were re-examined
16 months «post exposure», by use of repeated questionnaires and measurements of nerve
conduction velocities. We also examined possible visual effects of acrylamide exposure at 16
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months “post exposure” by measuring visual evoked response (VER) and electroretinography
(ERG) in the 24 workers.
4.2.2  Exposure assessment
No measurements of acrylamide or NMA in the working environment had been performed
during the injection work. Thus, the exposure assessment had to be mainly based on qualitative
exposure information.  The two available sources for quantitative exposure information were
the measurements of acrylamide and NMA in tunnel water, measured in the period after the
injection work had been stopped, and measurements of hemoglobin adducts to acrylamide,
analysed in blood samples taken from 2-5 months after the cessation of the injection work.
The estimated average amount of Roca-Gil (in kg) used per week are shown in Figure 1 A. This
information was used to estimate the weighted injection time described in 4.2.2.2. Figure 1B
and 1C shows measurements of acrylamide and methylolacrylamide in the tunnel water.  Figure
1D shows time and number of blood samples collected for measurements of acrylamide-protein
adducts
 4.2.2.1  Measurements of acrylamide and NMA in tunnel water
Due to the technical and environmental problems with the water leakages, the tunnel
construction work came to a halt on the 25 th  of August 1997.  Before this time, only a few
sporadic measurements of acrylamide were analysed from the water draining from the tunnel.
The highest concentrations were measured on the 25th of August, with 9654 µg/L acrylamide
and 16600 µg/L NMA (Sverdrup et al., 1999). During September, the average concentration of
acrylamide was 100-110 µg/L, and during October 1997 – April 1998 the majority of the
measurements were below 50 µg/L (see Figure 1).
“Post injection» was performed with 116 000 kg of an isocyanate containing grouting agent,
TACCS (45% difenylmetan-4,4-diisocyanat (MDI),  50% di-n-butylftalat and 5%
heksadekyldimetylamin (HDMA)).  During this work, several bore holes with unpolymerised
Rhoca Gil were discovered, and very high concentrations of acrylamide were measured in these
holes and in the water dripping from the adjacent tunnel wall. The highest concentration was
90.6 mg/L.  These observations indicate that skin exposure through contaminated tunnel water
could be of relevance to the workers, also in the period after the injection work came to a halt.
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Figure 1. Acrylamide use and concentration of acrylamides in tunnel water
and number and timing of blood sample collection for adduct determination
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4.2.2.2  Qualitative exposure information
Based on information obtained from the questionnaires, we estimated the cumulative time for
each worker had done tunnel work, together with the cumulative time of injection work during
the two-year period September 1995-August 1997.  We obtained information from the
construction company about the amount of Rhoca Gil used in the different parts of the tunnel in
the different periods (se figure 1A and B). The relevant exposure period was thus divided into
three subperiods, related to the injected volume of NMA grout:
Low volume injection period  (months) (LVP), from September 1995 - November 1996
High volume injection period (months) (HVP) from December 1996 - August 1997
Tunnel water exposure period (months) (TWP), from September 1997 – October 1997.
We also developed an exposure time index (ETI) which was the weighted cumulative exposure
time based on information on the amount of NMA grouts used in the different periods, where
the three periods were given weights of 2, 4 and 0.5 respectively.
For the analyses, we thus used a set of time-related indices:
• Tunnel time (TT): Total working time in the tunnel during 1995-97(months)
• Injection time (IT): Time with NMA grout injection (months)
• Exposure time index (ETI), based on weighted cumulative exposure time:
• Low volume injection period  (months) (LVP)
• High volume injection period (months) (HVP)
• Tunnel water exposure period (months) (TWP)
where ETI was estimated as:  (LVPx2) + (HVPx4) + (TWPx0.5)
Based on the questionnaires, we developed an intensity index, which was estimated as follows:
Injection of NMA grouts: Often:6, seldom:2, never:0
Mixing of NMA grouts : Often:2, seldom:1, never:0
Cleaning of NMA grouts Often:2, seldom:1, never:0
Spill of NMA on skin 3-0 , based on 5 questions on frequency and job task
Contaminated tunnel water on skin Yes:1,  no:0
Inhalation of NMA grouts Yes:1,  no:0
Thus, the intensity index was a sum score with the range: 1-15. In the analyses, we also used a
combined measure, multiplying the injection time (IT) with the intensity index.
24
4.2.2.3  Measurements of hemoglobin adducts to acrylamide
Analysis of hemoglobin adducts from acrylamide and N-methylolacrylamide
Hemoglobin (Hb) adducts derived from acrylamide and N-methylolacrylamide together with
ethylene oxide adducts were measured in blood samples at the Department of Environmental
Chemistry, Stockholm University. Hemoglobin (Hb) adducts of acrylamide in blood would
give a valid and sensitive estimate of the average exposure during preceeding months
(Bergmark 1997, Törnqvist 1994).  During October 1997 – January 1998 blood samples were
obtained from 24 exposed workers and 3 reference subjects, and were frozen for later analyses.
Half of the blood samples were taken 60-70 days after cessation of the injection work (Figure
1).  The rest were taken from 90 to 150 days after the injection work was stopped, thus
somewhat late to reflect exposure during injection work.
The analysis of adducts to N-terminal valines in hemoglobin (Hb) derived from acrylamide
and/or N-methylolacrylamide was performed by the N-alkyl Edman method with derivatization
and detachment of adducted valines with pentafluorophenyl isothiocyanate (PFPITC) and
analysis by gas chromatography tandem mass spectrometry (GC-MS/MS) as a derivative
detached from the globin: pentafluorophenyltiohydantoin (PFPTH), according to Törnqvist et
al. (1986), with modifications according to Bergmark et al. (Bergmark et al.,1993).
Acrylamide reacts with the N-terminal valine in Hb forming an N-(2-carbamoylethyl)valine
adduct detached from the globin as an N-(2-carbamoylethyl)valine-PFPTH (Bergmark et al.,
1993). In vitro and in vivo studies show that N-methylolacrylamide gives rise to an identical
derivative (see Paulsson et al., 2002). This fact means that we cannot distinguish between
acrylamide and N-methylolacrylamide exposure. The adduct level from an absorbed amount of
N-methylolacrylamide is about 25 and 35% ofthe level of an equivalent amount of acrylamide
in mouse and rat, respectively (Paulsson et al., 2001).
Sample preparation
Red blood cells were separated from the blood plasma by centrifugation (3000 x g) and 1.5
volume of water was added for lysis of the cells. The globin was precipitated by the addition of
the hemolysate to 50 mM HCl in 2-propanol, followed by pelleting by centrifugation (3,000 x
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g), first of the cell membrane and then, following addition of ethyl acetate, of the globin. The
precipitated globin was then dissolved in formamide and treated with the PFITC reagent at
near-neutral pH (at room temperature overnight and then at 45oC for 1 h). The alkylated N-
terminal valines, which detached from the globin as PFPTH`s, were separated by ether
extraction (Mowrer et al. 1989; Törnqvist, 1994).
Gas chromatography mass spectrometry analysis
The PFPTH derivatives were analysed by using a GC (Varian 3400) coupled to a triple
quadrupol MS (Finnigan TSQ700) in the chemical ionisation negative ions mode(NICI) (i.e.
electron capture ionization). The samples were injected via a septum equipped temperature
programmable injector (SPI, Varian) with temperature programme: 1 min at 100oC, 20 oC/min
to 240 oC, 10 oC/min to 320 oC, and then 320 oC for 7 min. The column used was a 30 m (0.32
mm i.d., 1.0 µm thickness) fused silica capillary column (DB-5MS, J&W Scientific). The GC
carrier gas was helium. The gas in the reaction chamber was methane (ion source temperature
150 oC and ionization energy 70 eV), and the collision gas was argon (collision chamber
pressure: 1.06 mTorr). For identification and quantitation of the PFPTH derivatives, MS/MS
analysis was performed by single reaction monitoring (SRM), using the product ions m/z=303,
304 and 319 formed from the precursor ion m/z=375, [M-20]-. For calibration and quantificat-
ion, an acrylamide alkylated reference globin and a synthesised deuterated internal standard (N-
(2-carbamoylethyl)[2H7]valine-PFPTH were used. These standard compounds were kindly
provided by E. Bergmark (Bergmark et al., 1993).
4.2.3  Examination of health effects
4.2.3.1  Symptoms
Symptoms related to the actual tunnel exposure were recorded for each participant at the initial
examination through a detailed questionnaire (Appendix 1). The information obtained here was
compared to the corresponding information obtained at the examination one year later.
4.2.3.2 Neurophysiological measurements. Initially, during October - December 1997, all
participants underwent neurophysiological  measurements (nerve conduction velocity, NCV) at
the Neurophysiological Laboratory, Ullevål Hospital, Oslo (Dr. Mona Heier and Hans
Sjöholm). Neurography was performed with measurements of motor nerve conduction velocity,
amplitude and F-latency in the right median, ulnar, peroneal and posterior tibial nerves.
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Sensory nerve conduction velocities and amplitudes were measured in the right median and
ulnar nerves with orthodromic stimulation in the palm and recording 7 cm from the stimulation
site at the volar side of the wrist. The sensory nerve conduction velocity and the amplitude of
the sural nerve were measured with antidromic stimulation approximately 10 cm. proximal to
the distal insertion of the Achilles tendon with the recording electrode placed below the lateral
malleolus. F-latencies were measured as the shortest latency from 20 successive optimal
stimuli. Nerve stimulation and the recording of nerve- and muscle action potentials were
performed with bipolar surface electrodes according to established, standardised procedures
using a 4 channel «Dantec Keypoint». All subjects participated at both examinations. Owing to
technical reasons, some measurements were not successful in a few of the subjects.
4.2.3.3   Visual evoked response (VER)
Visual evoked responses were recorded with pattern reversal stimulation of each eye
separately, with the other eye covered.  The cortical evoked response was recorded from
surface electrodes located at standard EEG-placements (O1, Oz and O2) over the occipital
region, with a frontal reference (Fz).  Latency to the maximum positive deviation from the
baseline (P100) was measured, as well as the latencies to the onset (N75) and end (N120) of
this potential.
4.2.3.4  Electroretinography (ERG)
Electroretinography was recorded with a surface electrode at the zygomatic arch just behind the
retinal plane with a reference at the lower eye lid in front of the retinal plane.  Photoptic
stimulation was given as flashes of white light with the frequencies 2 Hz and 30 Hz, with
normal indoor light conditions.  The amplitudes of the positive B-wave which is generated by
the photoreceptor cell of the retina and the adjoining bipolar cells were measured at both
frequencies.
4.2.4   GST genotyping of subjects and kinetic characteristics of different GSTs.
All the 25 exposed subjects and 50 referents were genotyped for the deletion polymorphism in
GSTM1 and GSTT1 and for the ile/val variation in codon 104 of the GSTP1 gene. DNA were
extracted from 100 µl blood and the polymorphic regions were amplified by PCR using
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previously described methods (Ryberg et al., 1997; Abdel-Rahman et al., 1996). The PCR
products were analysed by capillary electrophoresis using internal standards.
This genotyping was preceded by laboratory studies at our Toxicological Department, where
we examined kinetic parameters for glutathion transferase conjugation with different acryl-
amide compounds (acrylamide, bis-acrylamide, methylol-acrylamide) and glycidamide. Kinetic
parameters were determined for the following recombinant human glutathione S-transferase
isoenzymes using acrylamide and several acrylamide-like compounds as substrates: GSTM1-1,
GSTA1-1, GSTP1-1  and GSTT1-1. The reaction was initiated by the addition of [35S] GSH
(10 mM) and terminated by the removal of enzyme by centrifugation through Centriflex
protein-removal cartridges after 1 minute. The supernatants were immediately analysed by
high-pressure liquid chromatography (HPLC). The eluted peaks were collected in separate
tubes and radioactivity measured in a liquid scintillation analyser. Control incubations without
enzyme were run in each experiment. All kinetic data were corrected for the background
chemical reaction.
4.2.5  Chromosome studies
Chromosome studies were performed in the 25 exposed workers and a subsample of 25 tunnel
workers not exposed to Rhoca-Gil, matched for age, sex and smoking habits. Since it was
impossible to collect blood samples from the exposed worker and matched control on the same
day, seven additional subjects were recruited from the staff at the NIOH. One of them was
available for blood sampling each sampling day in order to control for possible postal and
culture factors. They were labelled laboratory controls.
Blood samples of 10 ml heparinized blood were collected from two exposed or control subject
together with one laboratory control on the same day and posted for delivery to Telemark
Central Hospital the next day. Four whole blood cultures for each subject were cultured for 50-
53 hours in Hams F10 medium with foetal calf serum, L-glutamin, gentamycin sulfate and
phytohemaglutinin. Colcemide was added to the cultures two hours before hypotonic treatment
with 0.75 M HCl and fixation with 3:1 metanol: acetic acid. Slides were stained in Giemsa and
chromosome damage was specified and scored in 200 metaphases per person on coded slides.
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All subjects answered a questionnaire at the time of the blood sampling on smoking habits, use
of mediccation, recent X-rays, allergy and infections, i.e. factors which may influence the
results.
All participants signed a declaration of consent to participate in the study.
4.2.6 Statistical methods
McNemar test for two related samples was used to test the difference between reported
symptoms (dichotomous variables) during exposure and 16 months post exposure (table 6-9).
When comparing the difference between neurographic measures in the exposed group and the
reference group, we used t-test for two unrelated samples (table 10,11,14,18-21). In order to
test for change in neurographic measures from 16 to 24 months post exposure, we applied the t-
test for two related samples (table 12-13). In the further assessment of the exposure-related
reversibility of outcomes, Spearman correlation coefficients were estimated in order to test the
association between the semi quantitative exposure indices and the change (in %) in the
neurographic measurements from four (T1)  to 16 months (T2) post exposure (T1 - T2) (table 15-
17). Mann-Whitney’s non-parametric ranking test was used for comparison between groups in
the chromosome studies. A step-wise linear regression test was also applied. The level of
statistical significance was set two-tailed at p<0.05.   The SPSS Statistical Package was applied
on a personal computer.
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4.3 RESULTS
4.3.1  Reported work tasks and exposures
All 24 index workers had taken active part in the injection of grouting agents (table 2). Four of
the workers had been exposed to NMA-based grouting agents in previous tunnel work.  The
tunnel workers had worked in Romeriksporten for 19.4 months on average (range 8-24
months). Twenty-one had injected Rhoca-Gil, 19 had mixed Solution 1 and 2, and 22 had taken
part in cleaning the equipment. We also asked how many days/shifts they injected Rhoca-Gil,
but the majority could not give information at such a detailed level. Seventeen of the 24
workers had done injection work for more than 18 months.
Table 2.  Reported work tasks during tunnel grouting (N=24)
Yes, total Yes, often
Work task n % n %
Injection work 24      100.0 21 87.5
Inj. of acrylamide grout 21 87.5 15 62.5
Mixing Solution 1+2 19 79.2 15 62.5
Cleaning of equipment 22 91.7 19 79.2
Repairing inj.equipment 14 58.4 10 41.7
Sampling   11 45.9   7  29.2
Mining 19 79.2 18 75.0
Drilling 18 75.0 13 54.2
Loading   9 37.5   7 29.2
Other    10 41.7   9 37.5
It can be seen from table 2 that the tunnel workers were involved in a variety of other work
tasks in the tunnel.  Thus, the work organisation was such that all the workers were expected to
be able to perform the various tasks in the tunnel.
Table 3.  Reported skin contact with acrylamide grout or contaminated tunnel water
                               Yes, total
Exposure (N)   Number    %
Skin contact with acrylamide grout (24)     19               79.2
Skin contact with tunnel water (23)     23   100.0
Completely wet from tunnel water (23)     23 100.0
Nineteen of the workers reported direct skin contact with Rhoca Gil, while all workers had
experienced skin contact with tunnel water (table 3).  In fact, all workers reported that they had
been »completely wet» from tunnel water.
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Table 4. Reported work tasks involving skin contact with acrylamide grout (N=24)
Yes, total Yes, often
Skin contact when: n % n %
Work with solution 1 14 58.3   5 20.8
Mixing before injection 16 66.7   7 29.2
Injection 17 70.8   6 25.0
Moving injection pins 15 62.5     4 16.7
Unpolymerised
acrylamide grout 11 45.8   2   8.3
Drainage work   2   8.3   0   - 
The majority of the workers reported tasks involving skin contact with Rhoca Gil during
injection (70.8%)and during mixing before injection (66.7%) or when moving injection pins
(62.5%) (table 4).
Table 5.  Use of protective clothing/equipment
Yes, total Usually Sometimes     Seldom
(N) n %  n %   n  %  n %
Rain trousers (22) 18   81.8 11 45.8   5 20.8 1   4.2
Rain jacket (22) 19   86.4   7 29.2 10 41.7 1   4.2
Gloves (23) 23  100.0 18 75.0   3 12.5 1   4.2
Changed wet clothes (24) 10   41.7   1   4.2   3 12.5 5 20.8
Respiratory protection (24) 12   50.0   1   4.2   4 16.7 6 25.0
All workers used gloves, while only 18 reported regular use (»usually») (table 4).  Eleven and
seven of the workers  «usually» wore  rain trousers and rain jackets, respectively.  Only one
subject “usually” changed wet clothes before the end of the shift, and only one reported
regularly use(“usually”) of respiratory protection.
4.3.2 Hemoglobin adducts to acrylamide
The first blood samples from the 24 workers were taken in October 1997, two months after
cessation of the injection work.  Most samples were taken later, from 2 to 5 months after the
injection work was stopped. The mean value of acrylamide adducts in the exposed group was
0.16 nmol/g hemoglobin (n=24, SD=0.17)) and 0.11 nmol/g hemoglobin (n=3, SD 0.08) among
the unexposed referents.  Only three workers had adduct levels exceeding 0.20 nmol/g
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hemoglobin (0.25, 0.28 and 0.89 nmol/g Hb, respectively). For these three workers, the samples
were collected 8-9 weeks after the last use of acrylamide-containing grouts.
Figure 2A shows acrylamide adducts plotted as a function of days from 24th October 1997, the
first date of blood sample collection. The 3 measurements marked red are from individuals
most likely exposed to acrylamide. In Figure 2B acrylamide adducts are plotted against
ethylene oxide adducts together with the regression line for the data shown as filled circles.
The three measurements marked red were not included in the regression computation. Since
smoking results in acrylamide adducts (Bergmark 1997), the regression line represents an
average background of acrylamide adducts due to smoking. Acrylamide adduct level for
exposed workers sampled 60 –70 days after cessation of the injection work (N=12) had a mean
adduct level of 0.20  (SD=0.23) compared to 0.12 among those sampled later.
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Figure 2. Acrylamide adducts and ethylene oxide adducts in blood
samples from exposed operators
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4.3.3  Symptoms
We repeated the symptom questionnaire at the 12 months follow-up examination, and were
able to compare the reported symptom prevalence during grouting work with the corresponding
figures 16 months post exposure. Table 6 shows the reported symptom prevalence related to the
peripheral nervous system at the two points in time.
Table 6. Reported symptoms related to the peripheral nervous system (PNS) during
grouting work and 16 months post exposure among 24 acrylamide exposed tunnel
workers
Symptoms           During exposure 16 months post exposure
related to PNS
                                                n          No.        %                   n        No.         %        
Paresthesia in hands 22   9 40.9 24 4 16.7
Pain in hands 21   5 23.8 24 2   8.3
Weakness in hands 24   3 12.5 24 4 16.7
Paresthesia in feet 23   7 30.4 23 5 21.7
Pain in feet 21   4 19.0 24 3 12.5
Cramps in feet 22   4 18,2 24 3 12.5
There was a lower prevalence of reported paresthesia in both hands and feet at the follow-up
examination, from 40.9 to 16.7% and from 30.4 to 21.7% respectively. There was also a
reduction in the prevalence of pain in hands from 23.8% to 8.3 %.  However, none of these
differences were statistically significant.
Table 7. Reported symptoms related to the central nervous system (CNS) during grouting
work and 16 months post exposure among 24 acrylamide exposed tunnel workers
Symptoms           During exposure 16 months post exposure
related to CNS    
n No.   %  n        No.         %
Headache 24 11 45.8 23 4 17.4
Nausea/d
izziness 24   9 37.5 23 1   4.3*
Concentration problems 23   5 21.7  23 2   8.7
Eye problems when reading 24   6 25.0 24 3 12.5
*p< 0.05
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For symptoms related to the central nervous system (CNS) (table 7), there was a statistically
significant reduction in the reported prevalence of nausea and dizziness from 37.5% during
grouting work to 4.3% 16 months post exposure. There was also a non-significant reduction in
the reported prevalence of headache, concentration problems and eye problems when reading.
Table 8. Reported symptoms related to the autonomous nervous system (ANS) during
grouting work and 16 months post exposure in 24 acrylamide exposed tunnel workers
Symptoms           During exposure 16 months post exposure
related to ANS
n No.  %  n        No.         %
Sweating, hands and feet 22   3 13.6 24 2   8.3
Diarrhoea 23   3 13.0 24 3 12.5
Voiding problems 24   1   4.2 24 0   0.0
Tachycardia 24   1   4.2 24 3 12.5
We also asked questions related to the autonomous nervous system, including sweating,
diarrhoea, voiding problems and tachycardia.  No statistically significant differences were
observed (table 8). Other symptoms are presented in table 9.
Table 9. Other symptoms reported during grouting work and 16 months post exposure in
24 acrylamide exposed tunnel workers
Symptoms               During exposure       16 months post exposure
n No. % n        No.        %
Cough 21 8 38.1 24 5 20.8
Throat irritation 22 7 31.8 24 3 12.5
Nose irritation 23 6 26.1 24 3 12.5
Eye irritation 22 4 18.2 24 4 16.7
Wheezing in chest 21 4 19.0 23 4 17.4
Breathlessness 22 6 27.3 23 4 17.4
Eczema, skin irritation 23 8 34.8 24 2   8.3*
Peeling of skin on hands 23 8 34.8 24 4 16.7
Attacs of white fingers 22 4 18.2 24 3 12.5
Attacs of white toes 22 2   9.1 24 0   0.0
*p< 0.05
The prevalence of reported symptoms from mucous membranes and upper airways were
consistently, but non-significantly reduced at the follow-up examination (cough, throat
irritation, nose/eye irritation). As the workers are exposed to many skin and airway irritants
during tunnel work, also including other grouting agents, these trends could just as likely be
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due to other exposure factors than Rhoca Gil. Skin irritaion is most  relevant in acrylamide
exposure. This was significantly reduced: from 34.8% during grouting work to 8.3 % at the
follow-up examination.  Another typical symptom reported among workers with skin contact
with acrylamide is peeling of the skin on the hands.  The reported prevalence was 34.8% during
grouting work, and 16.7% at the follow-up.
4.3.4  Nerve conduction velocities
Nerve conduction velocities (NCV) measured 4 months post exposure compared to correspond-
ing measurements in the reference group are shown in table 10. Statistically significant
differences in the measured mean NCV's were observed in the ulnar nerve only. There was a
statistically significant  lower velocity in the exposed group compared to the controls (52.3 vs.
58.9 m/s, p=0.001), and motor distal delay in the ulnar nerve was significantly prolonged (3.1
vs. 2.5ms, p=0.001).
Table 10. Mean nerve conduction velocities (NCV) in 24 acrylamide exposed
workers 4 months after the cessation of exposure compared to 50 referents.
Exposed (n=24) Referents (n=50)
Mean SD Mean SD p-value
Median nerve
   Motor NCV (m/s) 54.7 4,1 55.7c 5.9 0.46
   Sensory NCV (m/s) 53.5 5.5 53.6 8.3 0.94
   Distal delay (ms)   3.8 0.8 3,8 0.7 0.91
   F-response (ms) 24.5 1.8 24.5 2.9 0.98
Ulnar nerve
   Motor NCV (m/s) 57.9 6.1 55.9 6.8 0.23
   Sensory NCV (m/s) 52.3a 5.8 58.9d 8.5 0.001
   Distal delay (ms)   3.1 0.7   2.5 0.4 0.001
   F-response (ms) 26.0 2.2 25.5e 2.4 0.42
Sural nerve
   Sensory NCV (m/s) 47.0b 6.7 48.3e 5.8 0.41
Tibial nerve
   Motor NCV 44.2 4.3 43.2 4.7 0.37
   F-response (ms) 50.3a 6.2 50.4e 6.6 0.97
Peroneal nerve
   Motor NCV (m/s) 46.5 4.7 45.8 e 4.4 0.50
   F-response (ms) 48.1a 5.3 49.8f 5.3 0.21
 an=23  bn=21  cn=48  dn=46  en=49 fn=44
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The results from the corresponding amplitudes showed reductions in the sensory amplitude of
the median nerve (p=0.01) in the exposed, while there was a significantly elevated amplitude in
the motor amplitude of the median nerve compared to the referents (table 11). Sensory
amplitudes were not measurable in three exposed subjects and two referent subjects, thus
scored as zero.  Standard deviations were large.
Table 11.  Mean amplitudes in 24 acrylamide exposed
workers 4 months after the cessation of exposure compared to 50 referents.
Exposed Referents
Amplitudes Mean SD Mean SD p-value
Median nerve
   Motor (mV)   9.1   3.0   6.7   3.2 0.004
   Sensory (µV) 16.9 11.5 31.2 36.3 0.01
Ulnar nerve
   Motor (mV)   7.9   3.7   6.5   2.0 0.09
   Sensory (µV)   9.7a   6.9 13.1c 11.7 0.19
Sural nerve
   Sensory (µV) 12.0b   9.6   8.1 a   5.7 0.07
Tibial nerve
   Motor (mV)   4.3   2.6   4.4   2.2 0.83
Peroneus
   Motor (mV)   3.5   1.7   3.6   2.1 0.98
 a not elicited in one subject   b not elicited in 3 subjects c not elicited in 2 subjects
When comparing the neurographic results from 4 months post exposure with the corresponding
measurements one year later (table 12) there was a statistically significant improvement in
mean sensory NCV in the ulnar nerve from 52.9 m/s to 57.5 m/s (p=0.01), with a statistically
significant reduction in distal delay in the same nerve. In addition, a reduction in NCV was
seen for the sensory NCV in the sural nerve (p=0.045), and also a prolonged F-response in the
tibial nerve (p=0.01).
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Table 12.    Comparison of mean nerve conduction velocities 4 and 16 months after the
cessation of acrylamide exposure among 24 tunnel workers
4 months post exposure 16 months post exposure
Mean SD Mean SD p-value1
Median nerve
   Motor NCV (m/s) 54.7 4.1 54.5 6.3 0.92
   Sensory NCV (m/s)  (n=23) 53.4 5.5 52.5 7.0 0.47
   Distal delay (ms)   3.8 0.8   3.7 0.6 0.11
   F-response (ms) 24.5 1.8 25.0 2.0 0.10
Ulnar nerve
   Motor NCV (m/s) 57.9 6.1 58.1 7.7 0.90
   Sensory NCV (m/s)  (n=22) 52.9 5.3 57.5 7.4 0.02
   Distal delay (ms)   3.1 0.7   2.7 0.5 0.001
   F-response (ms) 26.0 2.2 26.5 2.0 0.19
Sural nerve
   Sensory NCV (m/s)  (n=20) 47.6 6.4 45.1 3.5 0.05
Tibial nerve
   Motor NCV 44.2 4.3 45.5 5.1 0.32
   F-response (ms)       (n=23) 50.3 6.2 51.9 5.7 0.01
Peroneal nerve
   Motor NCV (m/s) 46.5 4.7 46.4 4.8 0.91
   F-response (ms)     (n=23) 48.1 5.3 48.3 6.8 0.75
1Paired samples T-test. Paired differences.
Table 13.  Comparison of mean sensory (uV) and motor (mV) amplitudes among 24
acrylamide exposed workers 4 and 16 months after cessation of exposure.
4 months post exposure 16 months post exposure
Amplitudes No of pairs Mean SD Mean SD p-value
Median nerve
   Motor (mV) 24   9.1   3.0   8.4   3.5 0.36
   Sensory (µV) 24 16.9 11.5 35.5 35.1 0.01
Ulnar nerve
   Motor (mV) 24   7.9   3.7   5.7   1.9 0.01
   Sensory (µV) 24   9.7   6.9   9.5   7.7 0.94
Sural nerve
   Sensory (µV) 24 12.0   9.6   7.2   5.3 0.02
Tibial nerve
   Motor (mV) 24   4.3   2.6   4.3   2.1 0.94
Peroneus
   Motor (mV) 24  3.5   1.7   3.0   1.6 0.15
When amplitudes from four and 16 months post exposure were compared, the sensory
amplitude in the median nerve was significantly improved after one year. However, a
significant reduction of the sensory amplitude in the sural nerve and motor amplitude of the
ulnar nerve was also observed.
When the exposed workers were divided according to exposure time into a long time exposed
group (> 18months of injection work, n=17) and a short time exposed group (<18 months of
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injection work, n=7), an exposure response pattern was observed with significant differences
between the high exposed group and the references both for sensory NCV and distal delay in
the ulnar nerve 4 months post exposure (table 14). One year later, the measurements in the
exposed group approached the reference values, but only partially for distal delay.
Table 14.   Sensory NCV and distal delay in the ulnar nerve in 17 long time exposed
workers (≥18 months of injection) and 7 short time exposed workers (<18 months of
injection) 4 and 16 months after the cessation of exposure compared to 50 referents.
4 months                    16 months
post exposure              post exposure
Mean Mean
Ulnar nerve sensory NCV (m/s)
      High exposed (n=17) 51.8** 58.2
       Low exposed (n=7) 53.4 55.0
       Referents (n=46) 58.9
Ulnar nerve distal delay  (ms)
      High exposed (n=17) 3.14* * 2.70
       Low exposed (n=7) 2.99* 2.64
       Referents (n=50) 2.55
*p<0.05, **p<0.01, compared to referents
We have further examined the correlation between nerve conduction velocities measured 4
months post exposure, and the qualitative exposure indices (tunnel time, injection time,
exposure time index, intensity index and (injection time x intensity index)). For velocities
(measured in m/s), a negative correlation indicates an exposure-related reduction in NCV.  For
distal delay and F-responses (measured in ms), a positive correlation indicates a prolonged
response. These results are shown in table 15.
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Table 15. Correlation (Spearman correlation coefficients) between indices of acrylamide
exposure and neurographical measures 4 months post exposure (T1) in 24 tunnel workers
Tunnel
time
Injection
time
Exposure
time index
Intensity
index
Inj.time x
intensity index
Median nerve
   Motor NCV (m/s) -0.28 -0.16 -0.20 -0.09 -0.21
   Sensory NCV (m/s)  0.18 -0.02 -0.01 -0.003  0.004
   Distal delay (ms) -0.10 -0.11 -0.09 -0.03 -0.01
   F-response (ms) -0.21  0.08  0.10  0.11  0.13
Ulnar nerve
   Motor NCV (m/s) -0.07 -0.19 -0.19  0.004 -0.10
   Sensory NCV (m/s) -0.21 -0.19 -0.18  0.06 -0.08
   Distal delay (ms) -0.02 -0.11 -0.09 -0.19 -0.14
   F-response (ms) -0.05  0.18  0.20  0.28  0.29
Sural nerve
   Sensory NCV (m/s) -0.14 -0.33 -0.35 -0.22 -0.31
Tibial nerve
   Motor NCV (m/s)
NCV:  Nerve conduction velocity
The correlation coefficients were low for all measures, none were statistically significant.
To assess the possible exposure-related reversibility of NCV, we have examined the correlation
between indices of acrylamide exposure and the change (in %) in neurographical measurements
between 4 and 16 months post exposure (T1 - T2).  These are shown in table 16.
If a nerve conduction velocity, measured in meters/second, was reduced at 4 months post
exposure (T1) and then returned to normal after one year (T2), the T1 - T2 difference will be
negative.  The more negative it is,  the more improvement there is. If this improvement is
related to the level of exposure, a negative correlation coefficient will indicate an exposure-
related improvement during that year.  Correspondingly, for distal delay and F-responses,
which are measured in milliseconds, an improvement in the time period  T1 to T2 will result in a
positive T1 - T2 difference, and a positive correlation coefficient will indicate exposure related
improvement from 4 to 16 months post exposure.
Statistically significant negative correlation coefficients in the range of 0.45 – 0.54 were
observed between the change in both motor and sensory nerve conduction in the arms and
several of the surrogate variables for exposure level (tunnel time, injection time, exposure time
index and (injection time x intensity index)).  This indicates that those with the highest
exposures had the largest improvement in NCV from 4 to 16 months post-exposure.
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Correspondingly, the F-responses in the median and the ulnar nerve show significant positive
correlations for the same exposure indices, indicating an improvement in this sensitive measure
of peripheral nerve conduction.  No statistically significant correlations were observed for
nerves in the lower extremities. It can further be seen that the time-related exposure indices
(tunnel time, injection time, injection time index) are those with the highest correlation
coefficients, while the correlations with the questionnaire-based intensity index were very low.
Table 16.  Correlation (Spearman’s rank correlation coefficients) between indices of
acrylamide exposure and the improvement (in %) in neurographical measures from 4 to
16 months post exposure.
Improvement
 (in %)
Tunnel time Injection time Exposure
time index
Intensity
index
N Mean SD
Median nerve
   Motor NCV (m/s) 24   0.3 14.2 0.45* 0.35 0.39 0.33
   Sensory NCV (m/s) 23 -1.5 10.4 0.49* 0.54** 0.54** 0.08
   Distal delay (ms) 24 -2.8 11.4 0.02 -0.08 -0.06 0.23
   F-response (ms) 24   2.1 5.8 0.22 0.53** 0.53** 0.16
Ulnar nerve
   Motor NCV (m/s) 24   0.7 11.6 0.13 0.36 0.36 -0.14
   Sensory NCV (m/s) 22   9.5 15.9 0.54* 0.53* 0.53* -0.04
    Distal delay (ms) 24 -11.7 14.7 0.03 -0.08 -0.06 -0.13
   F-response (ms) 24   2.7 9.1 0.40 0.48* 0.50* 0.34
Sural nerve
   Sensory NCV (m/s) 20 -4.1 9.5 0.05 0.33 0.32 0.26
Tibial nerve
    Motor NCV (m/s) 24 3.4 13.1 0.29 0.10 0.12 0.31
Peroneal nerve
    Motor NCV (m/s) 24 0.1 8.8 0.06 0.19 0.19 0.22
   F-response (ms) 23 2.1 5.8 -0.01 0.22 0.19 0.01
NCV:  Nerve conduction velocity * p<0.05      ** p<0.01
From table 16 it can also be seen that the mean change in measured values (in %) from time T1
to T2  goes in both directions, which corresponds with the results in table 12.  For the F-
responses there are significant positive correlation coefficients with exposure, indicating an
improvement after one year in those with the highest exposures, even if the mean difference is
slightly in the opposite direction.
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Table 17. Correlation (Spearman’s rank correlation coefficients) between indices of
acrylamide exposure and the change (in %) in amplitudes between 4 and 16 months post
exposure (T1 - T2).  (a negative correlation indicates improvement from T1 to T2 )
T1 - T2
(in %)
Tunnel
time
Injection
time
Exposure
Time index
Intensity
index
Inj.time x
intensity index
Amplitudes N Mean SD
Median nerve
   Motor (mV) 24 -1.2 45.9 -0.47* -0.38 -0.40 -0.06 -0.31
   Sensory (µV) 24 -139.0 186.5 0.18 0.11 0.14 0.30 0.27
Ulnar nerve
Motor (mV) 24 17.6 36.0 0.04 -0.02 -0.003 0.01 0.02
   Sensory (µV) 23 -18.2 105.1 -0.31 -0.39 -0.38 -0.10 -0.21
Sural nerve
   Sensory  (µV) 21 39.9 42.2 0.14 -0.09 -0.08 0.12 0.05
Tibial nerve
   Motor (mV) 24 -40.5 147.5 -0.13 -0.02 -0.06 -0.41* -0.34
Peroneal nerve
   Motor (mV) 24 -0.85 63.4 0.05 0.11 0.09 0.10 0.12
The corresponding amplitudes are shown in table 17. There are relatively large mean
differences between the two measurements, with corresponding large confidence intervals and
correlation coefficients which are both negative and positive. The only statistically significant
correlations were observed for the median motor nerve (tunnel time) and tibial motor nerve
(intensity index), indicating exposure-related improvements in the amplitude response after one
year.
4.3.5  Visual evoked response and electroretinography
At the examination 16 months post exposure, visual evoked responses (VEP) and electroretino-
graphy (ERG) were measured in all 24 workers, and compared to the 50 unexposed tunnel
workers.  The measured P100 VEP latencies and ERG amplitudes at 2 and 30Hz stimulation for
both eyes are shown in table 18.
42
Table 18.  Mean visual evoked response (VEP) latency and electroretinography (ERG)
amplitude in 24 workers 16 months after cessation of acrylamide exposure, compared to
50 referents
Exposed Referents
Mean        N SD Mean       N SD p-value
Visual evoked response
   P 100  right   (ms) 105.3        24 11.1 102.7      50 7.9 0.26
   P 100  left     (ms) 105.1        24 11.6 101.9      50 6.9 0.14
Electroretinography
   2 Hz   right   (uV) 12.4          22 3.2 13.4        49 4.9 0.32
   2 Hz   left     (uV) 11.8          22 3.5 13.4        49 6.2 0.18
 30 Hz   right   (uV) 7.3            22 2.6 9.5          48 4.7 0.02
 30 Hz   left     (uV) 7.4            22 2.6 9.7          49 4.8 0.04
For the P100, the latency is slightly longer in among the exposed subjects, however, it is not
statistically significant. The amplitudes measured in the ERG were also lower in the exposed
subjects than in the referents.  The differences with the 30 Hz stimulation frequency were
statistically significant for both eyes.
4.3.6 Glutathion S-transferase genotypes.
Prior to the susceptibility study the kinetic parameters of glutatione S-transfereases were
determined in vitro using recombinant enzymes (see Methods). The uncatalyzed reaction
between the metabolite glycidamide and glutathione was very high, which made the
determination of the parameters impossible. For acrylamide the specific enzyme activity was
highest for GSTA1-1 (5.3 µmol/min/mg), followed by T1-1 (4.6 µmol/min/mg), M1-1 (1.3
µmol/min/mg) and P1-1 (1.1 µmol/min/mg). The GSTT1-1 enzyme had the highest affinity for
acrylamide (Km = 5.4 mM) and the other GSTs about 30% lower (Km 30% higher).
The gluthathion transferase gene for the M1 and T1 enzyme were genotyped in all 25 exposed
subjects.  In the general Norwegian population, 50% lack  M1 and 15% lack the T1.  In this
small sample, 12 of the subjects were M1- and only 4 were T1-. All T1- subjects were also M1-
.
The results from selected nerve conduction velocity measurements, stratified for Glutathion S
transferase (GST) genotypes M1± are shown in table 19.
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Table 19. Neurographical results in 24 acrylamide exposed workers 4 months after
cessation of exposure, stratified for Glutathion S transferase genotype M1±.
Exposed Exposed
M1- Mean
(n=12)
SD M1+ Mean
(n=12)
SD p-value
Median nerve
   Motor NCV (m/s) 55.5 5.0 53.8 3.1 0.33
   Sensory NCV (m/s) 54.4 6.3 52.6 4.5 0.44
Ulnar nerve
   Motor NCV (m/s) 57.6 6.2 58.2 6.2 0.83
   Sensory NCV (m/s) 52.9a 6.7 51.8 5.0 0.66
an=11
On the group level, no differences in the nerve conduction velocities, as measured 4 months
post exposure, were observed when the 12 exposed tunnel workers with genotype M1- were
compared to the 12 exposed workers with genotype M1+. Neither were any differences
observed for the T genotypes (not presented, owing to the small over all figures, together with
the skewed distribution of the T genotypes).
We have also compared the change in selected neurographical measures between 4 and 16
months post exposure for the M1- and M1+ subjects respectively.   No statistically significant
differences were observed between the two groups (not shown).
The results from the visual evoked response (VEP) and electroretinography (ERG)
measurements, stratified for Glutathion S transferase (GST) genotypes M1± are shown in table
20.
The P100 were slightly longer among the M1+ subjects, but no differences between the groups,
neither in VEP or ERG were statistically significant. The corresponding results for GST
genotypes T1± are shown in table 21.
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Table 20. Visual evoked response (VEP) and electroretinography (ERG) in 24 workers 16
months after the cessation of acrylamide exposure, stratified for GST - M genotype (M1±)
Exposed
M1-
Exposed
M1+
Mean
(n=12)
SD Mean
(n=12)
SD p-value
Visual evoked response
   P 100  right   (ms) 102.7 6.1 107.8  14.4 0.28
   P 100  left     (ms) 102.3 8.0 108.0  14.1 0.23
Electroretinography
   2 Hz     right 12.9 3.2   11.8a   3.2 0.42
   2 Hz     left 12.5 4.4   11.2   2.3 0.35
 30 Hz     right 7.6 2.7     7.0a   2.7 0.61
 30 Hz     left 7.2 2.5     7.7a   2.8 0.68
 an=10
Table 21. Visual evoked response (VEP) and electroretinography (ERG) in 24 workers 16
months after the cessation of acrylamide exposure, stratified for GST - T genotype (T1±)
Exposed
T1-
Exposed
T1+
Mean
(n=4)
SD Mean
(n=20)
SD p-value
Visual evoked response
   P 100  right   (ms) 100.6   4.4 106.2 11.9 0.37
   P 100  left     (ms)   98.2   3.2 106.5 12.2 0.19
Electroretinography
   2 Hz     right   13.0   0.8  12.3a   3.5 0.46
   2 Hz     left   16.1   3.5  11. 0   2.9 0.01
 30 Hz     right     9.4   1.8    6.9a   2.6 0.08
 30 Hz     left     8.7   1.7    7.1a   2.7 0.27
an=18
Reduced amplitudes were observed in the ERG in the T1+ subjects compared to T1- subjects
for 2 Hz, left eye, and for 30 Hz, right eye respectively. The figures are small, however,
particularly in the T1- stratum.
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4.3.7  Chromosome studies
Chromosome examinations were performed for all the 25 exposed subjects, 25 age and
smoking matched controls (unexposed tunnel workers) and seven laboratory controls.  The
chromosome results which are reported are the number of cells with aberrations (excluding
gaps), the number of chromatid breaks, the number of chromosome breaks, the number of
chromatid gaps and the number of chromosome gaps, all as group means per 200 cells.
Comparisons between all the exposed subjects and the control workers and laboratory controls
are shown in table 22. Seven laboratory controls were sampled altogether 31 times and the
mean values are reported.  There were no striking differences between the groups. Only the
number of chromatid gaps was significantly different between the exposed subjects and the
matched controls.
Table 22.  Chromosomal aberrations for all the exposed workers with the controls and the
laboratory controls.  Mean number per 200 cells with standard deviation in brackets.       
                    N
Number of
cells with
aberrations a
Number of
chromatid
breaks
Number of
chromosome
breaks
Number of
chromatid
gaps
Number of
chromosome
gaps
Exposed 25 2,9 (1,7) 1,4 (1,1) 1,2 (1,1) 10,6 (5,6)b 1,5 (1,5)
Controls 25 2,4 (1,6) 0,9 (1,2) 0,9 (0,9) 6,4 (4,4) 1,4 (1,7)
Lab. Controls   31c 2,7 (1,4) 1,2 (1,1) 1,3 (1,1) 8,6 (4,7) 1,6 (1,2)
a   Excluding gaps.
b   Mann-Whitney’s non- parametric test between exposed and control. p = 0,004 (2 tailed).
c   Seven persons sampled repeatedly, 31 times in all, as a control of the method.
In order to look for a possible skewed distribution of aberrations between the groups we
compared the number of persons with aberrations ≥ 3, as shown in table 23.
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Table 23.  Number of exposed workers compared to laboratory controls sampled at the
same time, and number of controls compared to laboratory controls sampled at the same
time with scores ≥3 for three groups of chromosomal aberrations.
Number of cells
with aberrations a
N
Number of chromatid
breaks
N
Number of chromosome
breaks
N
Exposed workers 14 4 2
Lab. Controls 8 3 3
Controls 9 3 1
Lab. Controls 8 1 2
a   Excluding gaps
A slightly higher number of exposed persons was found with the number of cells with
aberrations above the cut off point. As the controls and laboratory controls show similar results,
we are fairly confident that we have no differences due to methodological factors. In the
following, therefore, only comparisons between exposed workers and matched controls are
shown.
Eighteen workers were exposed to more than 500 days with injection of Rhoca-Gil.  We
compared these workers to their matched controls and to the seven workers with lower
exposure, as shown in table 24.
Table 24. Chromosomal aberrations in the long time exposed workers (≥ 18 months of
injection work) and short time exposed workers (<18 months of injection work) and
matched control subjects.   Mean number per 200 cells with SD in brackets.
                       N
Number of
cells with
aberrations a
Number of
chromatid
breaks
Number of
chromosome
breaks
Number of
chromatid
gaps
Number of
chromosome
gaps
Long time
exposed
18 2,9 (1,7) 1,3 (1,0) 1,1 (1,1) 10,5 (6,0)b 1,2 (1,4)
Matched controls 18 2,9 (1,7) 1,2 (1,3) 1,1 (1,0) 6,5 (5,0) 1,7 (1,9)
Short time
exposed
7  2,9 (1,7)b 1,6 (1,4) 1,3 (1,1) 10,7 (4,7)b 2,1 (1,8)
Matched controls 7 1,3 (0,5) 0,3 (0,5) 0,4 (0,5) 6,0 (2,8) 0,9 (0,7)
a   Excluding gaps
b   Mann-Whitney’s non-parametric test between exposed and control: p= 0,05 (2 tailed)
There were no differences between the high and low exposed workers. Only for chromatid gaps
there was a significant difference between the workers and their matched controls. All the
exposed workers are treated as one group in the following.
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Comparing exposed smokers and non-smokers to their respective controls (table 25) did not
reveal any significant differences except for chromatid gaps.
Table 25.   Chromosomal aberrations for exposed workers and controls grouped as
smokers and non-smokers. Mean numbers per 200 cells with SD in brackets.
                       N
Number of
cells with
aberrations a
Number of
chromatid
breaks
Number of
chromosome
breaks
Number of
chromatid
gaps
Number of
chromosome
gaps
Exposed
smokers
   12 2,5 (1,7) 1,2 (1,1) 0,8 (0,9) 10,2 (6,5) 1,3 (1,2)
Control
smokers
14 2,6 (1,6) 0,8 (1,0) 0,9 (0,9) 6,8 (4,0) 1,7 (2,2)
Exposed
non – smokers
13 3,3 (1,7) 1,5 (1,1) 1,5 (1,2) 10,9 (4,8)b 1,6 (1,8)
Control
non – smokers
11 2,2 (1,6) 1,1 (1,4) 0,9 (1,0) 5,8 (5,1) 1,1 (0,7)
a   Excluding gaps
b   Mann-Whitney’s non-parametric test between exposed workers and controls:  p= 0,007 (2 tailed)
We also grouped the exposed workers according to smoking habits and GSTM 1+ and
GSTM 1- (table 26). The number of chromatid gaps was only significantly different for the
group of workers with GSTM1- compared to their GSTM1- controls As shown in the table this
was mainly due to the difference found between the exposed non-smokers and their non-
smoking controls.
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Table 26. Chromosomal aberrations in exposed workers and controls grouped according
to genotype GSTM1 ± and smoking. Mean numbers per 200 cells with SD in brackets.
                       N
Number of
cells with
aberrations
a
Number
of
chromatid
breaks
Number of
chromosome
breaks
Number of
chromatid
gaps
Number of
chromosome
gaps
Exposed workers
GSTM1 -
13 2,7 (1,5) 1,5 (1,1) 1,0 (0,9) 12,2 (6,9)b 1,6 (1,9)
Controls GSTM1 - 15 2,3 (1,6) 1,0 (1,2) 0,7 (0,7) 6,5 (6,5) 1,2 (1,2)
Exposed workers
GSTM1 +
12 3,2 (1,9) 1,3 (1,2) 1,3 (1,3) 8,8 (2,9) 1,3 (1,1)
Controls GSTM1 + 8 3,1 (1,6) 1,0 (1,2) 1,5 (1,1) 6,3 (5,5) 2,0 (2,8)
Exposed smokers
GSTM1 -
6 2,0 (1,4) 1,2 (0,8) 0,5 (0,5) 13,0 (8,3) 1,0 (1,3)
Control smokers
GSTM1 -
7 2,6 (1,7) 1,0 (1,0) 0,7 (0,8) 8,7 (3,9) 1,0 (1,0)
Exposed smokers
GSTM1 +
6 3,0 (1,9) 1,2 (1,5) 1,2 (1,2) 7,3 (2,5) 1,7 (1,2)
Control smokers
GSTM1 +
5 3,4 (1,3) 0,8 (1,1) 1,4 (0,9) 4,6 (3,8) 3,0 (3,2)
GSTM1 – exposed
non – smokers
7 3,3 (1,4) 1,7 (1,3) 1,4 (1,0) 11,6 (6,1)b 2,1 (2,2)
GSTM1 - control
non – smokers
8 2,0 (1,5) 1,0 (1,4) 0,6 (0,7) 4,6 (3,7) 1,4 (0,5)
GSTM1 + exposed
non – smokers
6 3,3 (2,1) 1,3 (1,0) 1,5 (1,5) 10,2 (2,8) 1,0 (0,9)
GSTM1 + control
non – smokers
3 2,7 (2,1) 1,3 (1,5) 1,7 (1,5) 9,0 (7,8) 0,3 (0,6)
a   Excluding gaps
b   Mann-Whitney’s non-parametric test between exposed and control: p= 0,02 (2 tailed)
The corresponding results for GST1± are shown in Table 27. We did not stratify the
participants according to smoking habits for genotype GSTT1, however, as the number of
persons was so small.
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Table 27.  Chromosomal aberrations in exposed workers and controls grouped according
to Genotype GSTT1 ±. Mean numbers per 200 cells with SD in brackets
     
                       N
Number of
cells with
aberrations a
Number
of
chromatid
breaks
Number of
chromosome
breaks
Number of
chromatid
Gaps
Number of
chromosome
      gaps
Exposed workers
GSTT1-
    4 3,8 (1,3) 1,8 (1,3) 1,8 (1,0) 16,3 (2,2) 2,3 (2,6)
Controls GSTT1- 5 2,0 (1,7) 0,8 (1,3) 0,8 (1,1) 9,6 (5,9) 1,0 (1,2)
Exposed workers
GSTT1+
21 2,8 (1,7) 1,3 (1,1) 1,1 (1,1) 9,5 (4,1)b 1,3 (1,2)
Controls GSTT1+ 18 2,7 (1,6) 1,1 (1,2) 1,0 (0,9) 5,6 (4,0) 1,6 (1,9)
a   Excluding gaps
b   Mann-Whitney’s non-parametric test between exposed and control: p= 0,005 (2 tailed)
From table 27 it can be seen that the highest frequencies for all effect parameters are found for
the exposed workers with GSTT1- compared to the matched controls even if the differences are
not significant. The same trend is observed in Table 28 where the participants are grouped
according to both GSTT1 and GSTM1.
Table 28.  Chromosomal aberrations in exposed workers and controls grouped according
to the combination of genotypes GSTM1 ± and GSTT1 ±. Mean numbers per 200 cells
with SD in brackets.                                                   
                         N
Number of
cells with
aberrations a
Number of
chromatid
breaks
Number of
chromosome
breaks
Number of
chromatid
gaps
Number of
chromosome
gaps
Exposed workers
GSTM1- GSTT1 -
4 3,8 (1,3) 1,8 (1,3) 1,8 (1,0) 16,3 (9,2) 2,3 (2,6)
Controls
GSTM1-  GSTT1 -
3 1,3 (0,8) 0,3 (0,6) 0,7 (1,2)  8,7 (4,2) 1,7 (1,2)
Exposed workers
GSTMI- GSTTI+
9 2,2 (1,4) 1,3 (1,0) 0,7 (0,7) 10,4 (5,3)b 1,3 (1,5)
Controls
GSTM1- GSTT1+
12 2,5 (1,7) 1,2 (1,3) 0,7 (0,7) 6,0 (4,3) 1,1 (0,7)
Exposed workers
GSTM1+ GSTT1+
12 3,2 (1,9) 1,3 (1,2) 1,3 (1,3)  8,8 (2,9)b 1,3 (1,1)
Controls
GSTM1+ GSTT1+
6 3,2 (1,3) 0,8 (1,0) 1,7 (1,0) 4,7 (3,4) 2,7 (3,0)
a   Excluding gaps
b   Mann-Whitney’s non- parametric test between exposed and control: p= 0,07 and 0,02 (2 tailed)
No exposed workers with GSTM1+ and GSTT1 -.
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Owing to the small numbers in the groups there are no significant differences between
GSTM1-/GSTT1- workers and controls, but the trend is similar for all the effect parameters
studied. The only significant differences are found in the number of chromatid gaps.
Stepwise linear regression analysis was performed with the parameters exposed/controls,
smoker/non-smoker, use of medication (yes/no), GSTM1+/GSTM1-, GSTT1+/GSTT1- in the
model. Exposure and genotype GSTT1 came out as significant for the number of chromatid
gaps only with p=0.002 and p=0.004 respectively. More controls than exposed persons used
medication regularly, but for both groups the people using medicine had lower frequencies of
all types of chromosomal aberrations than the people not using medication.
The other variables asked for in the questionnaire such as X-ray exposure, infections and
allergy, could not be included in the analysis because of too many missing values. However,
the missing values were equaly distributed when comparing the exposed workers and the
controls. Two persons in each group reported allergy problems. One had a high number of
aberrations and the other had low number of aberrations.
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4.4. Discussion
The results from this study indicate slight effects on the nervous system related to exposure to
N-methylolacrylamide and acrylamide in 24 tunnel workers during grouting operations in
tunnel work. Based on examinations and measurements performed 4 and 16 months after the
cessation of the most relevant exposure, the effects seemed largely to be reversible, with
normalisation after one year. Indications of a possible cytogenetic effect, expressed as an
increased number of chromatide gaps among the exposed workers was also observed.
However, several aspects related to the design, the exposure conditions, and the specific results
of this study need to be further discussed.
4.4.1  Validity aspects
The study was performed as two cross-sectional examinations of those 25 exposed tunnel
workers judged to be among the highest exposed from a study base of 73 eligible tunnel
workers who participated in the OHS survey of the construction company.  The participation in
the OHS survey was complete for all relevantly exposed subjects, independent of symptom
status. However, the selection of the 25 subjects for the follow-up study was performed after
the OHS survey was initiated, and was thus particularly vulnerable to outcome dependent
selection. The use of a thorough selection procedure, based on detailed information from the
company, the workers and their representatives, and interviews and questionnaires from the
OHS survey makes us fairly convinced that the subject selection was based on exposure
criteria, exclusively, and not on subjective symptoms or other effects.  Three workers who did
not fullfill the exposure criteria were also examined with the same methods as the index group
at their request, but they were not included in the epidemiological study.  Subjects with known
neurological disease, diabetes mellitus, or alcoholism were not eligible for the study.  However,
one subject who during the examinations was discovered to have diabetes, was excluded from
most analyses, but was maintained in the genotoxic part of the study.
Several procedures were chosen in order to establish relevant contrasts in the study of
exposure-outcome relationships. One was the establishment of an external reference group.
Another was the performance of internal comparisons within the exposed group related to
surrogates of exposure level. For the study of the possible reversibility we measured the same
response in each individual at two different points in time.
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The optimal reference group is comparable to the index group, except for the actual exposure
under study. Other tunnel workers, who did not perform injection work with NMA-containing
grouts would fullfill these requirements. Thus, the 50 reference tunnel workers selected for the
other study on possible late effects of  NMA-exposure (Goffeng et al., 2000) were also used as
referents in the neurophysiological part of the study.  For the chromosome studies, a subsample
of  25 unexposed reference subjects was selected, matched on age (+/- 3 years) and smoking
status (present/former/never). The matching criteria were not so strict for two subjects, but we
believe that this does not influence the comparability between the groups.
Tunnel workers are exposed to a variety of exposure factors, which could in part confound the
examined effects. Thus, exposure to other neurotoxic agents, such as organic solvents, lead or
other metals, together with vibration exposure could have influenced the observed effects.   In
addition, their exposure to other factor related to life style, such as smoking, might also be
different from the general population (Ulvestad et al., 2000).   The distribution of these factors
was comparable between the groups (table 1).  Thus, we believe that the reference group
secured the necessary comparability between the groups.
Owing to previous reports on the potential reversibility of acrylamide-related effects, the
second examination was performed 12 months after the first examination. In these analyses,
intra- individual comparisons were performed, thus avoiding between-group confounding. All
subjects participated at both examinations.  However, owing to technical reasons, some
measurements were not successful in a few of the subjects.
4.4.2  Exposure assessment
When evaluating both the positive and non-positive results from this study, a crucial issue is to
assess the «dose», i.e. the time-related concentrations of NMA and acrylamide monomer that
the workers were exposed to.  However, no reliable quantitative measurements of exposure
were performed in this study.  Thus, no information on such quantitative dose-response
relationships can be given.  Firstly, no measurements of acrylamide or NMA in the working
atmosphere were performed. In fact, the workers themselves were not informed that the grout
contained acrylamide when performing the injection work, due to incomplete material safety
data sheets.
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The concentrations of acrylamide and NMA in tunnel water immediately after the injection was
stopped could provide a crude indicator for recent exposure, not only during injection work, but
also during other tasks.  Thus, all workers reported contact with tunnel water, and that they
were completely wet from tunnel water.  The observation of very high concentrations of
acrylamide (90.6 mg/L) in water dripping from bore holes of unpolymerised grouting agent in
January 1998 indicates the possibility of relevant exposure also after the injection period.
However, it is believed that the exposure after the cessation of the injection work was radically
reduced for most workers.  Another rather unexpectedly source of exposure was reported by
some of the workers.  It was a common assumption that tunnel water was pure, and
consequently the workers used this water for making their coffee during breaks inside the
tunnel. To what degree this was common practice is unclear, but it is not believed that this oral
intake of potentially polluted water contributed much to their cumulative exposure.
Hemoglobin (Hb) adducts of acrylamide in blood will give a valid and sensitive estimate of the
average exposure during the preceding months (Bergmark, 1997, Törnqvist et al., 1994,
Hagmar et al., 2001). This critical time window of up to 4 months post exposure is related to
the about 120 days average life span of the erythrocytes. The first blood samples in the 25
workers were taken in October 1997, two months after cessation of the injection work.  Most
samples were taken later, from 2 to 5 months after the injection work was stopped.  Due to the
uncertainty with regard to the possible exposure to acrylamide in tunnel water after the
grouting work came to a halt, we still chose to analyse all the samples. When adjusted for the
levels of acrylamide that can be attributed to smoking, only 3 subjects had elevated adduct
values, of 0.25, 0.28 and 0.89 nmol/g Hb, respectively. All these samples were taken in
October.
Bergmark has recently shown that acrylamide adducts are associated with smoking (Bergmark
1997) and ethylene oxide has also been shown to be associated with smoking (Törnqvist et al.,
1986). When “adjusting” for the potential effect of smoking on the acrylamide adduct levels, by
the use of corresponding etylene oxide adducts (Figure 4), only 3 subjects had “unexplained”
elevated acrylamide adduct levels. It is therefore reasonable to suggest that the 3 elevated
measuremets are related to occupational exposure. An alternative, but less likely explanation
would be related to diet, which recently has been in focus as a potential source for acrylamide
exposure (Tareke et al., 2002).  We have no information on diet habits among the participants,
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however.  The observation of generally low adduct levels in the samples taken more than 70
days after cessation of the injection work, strengthen the suggestion that the tunnel water was
not an important source of exposure after the injection work was stopped.
It is also of interest to compare the exposure conditions in the Swedish and Norwegian tunnel
projects.  In Hallandsåsen in Sweden, about 1500 tons of the NMA grout was used during 6-8
weeks, while in Romeriksporten, 340 tons were used during a two-year period.  In the 210
Swedish workers, 36 had Hb adduct values between 0.30-1.00 nmol/g Hb, and 38 had >1.00
nmol/g Hb, with the highest value measured to 17.7 nmol/g Hb (Hagmar et al., 2001). Their
blood samples were taken 1 to 5 weeks after the cessation of exposure.
Assuming that exposure had been going on for four months or more, i.e. with a steady-state Hb
adduct level been established, the Hb adduct level will decay in a quadratic function (Formula
7 in Granath et al., 1992). For instance a sample collected 38, 83 or 100  days after cessation of
exposure contain 49, 12 and 5  %, respectively,  of the steady-state adduct level of a even
continuous exposure.  The results indicate that exposures have not been high and that the
exposure levels during injection work were higher at the tunnel construction in Hallandsåsen
than in Romeriksporten.
The results show, however, that some of the examined persons reach total acrylamide adduct
levels (including contribution from background exposure and smoking) near or above the no-
effect threshold level of about 300 pmol/g globin estimated for light, mostly reversible,
neurotoxic  symptoms (Törnqvist et al., 1998 with data from Calleman et al., 1994; Hagmar et
al., 2001). In agreement with this, light neurotoxic symptoms have been observed in the present
study, a fact that underlines the earlier finding that the no-effect threshold in humans for light
neurotoxic symptoms may be much lower than the threshold value estimated from animal
experiments. The value 300 pmol/g globin (from an exposure lasting more than 4 months)
corresponds to an uptake of acrylamide of about 10 µg/kg and day (Törnqvist et al., 1998 with
parameter values from Calleman 1996). From animal experiments a no-effect threshold
corresponding to 500 µg/kg and day is estimated (Johnson et al., 1986; WHO, 2002).
In lack of reliable quantitative exposure data, we aimed at optimising the use of  qualitative
exposure data. Thus, a set of surrogate variables was developed based upon the available
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information from the company, the occupational health service, from interviews and several
questionnaires. When comparing the different approaches, it seemed that the information on
time with injection work (in months) was the best predictor of the NCV reversibility outcomes.
This was only marginally improved when the different time periods were given weights
according to the amount of NMA grout used (Kjuus et al., 2001). The intensity index, based
upon questionnaire data on the frequency of the different working tasks, did not at all predict
the outcome.  As the workers were not able to answer how many shifts they had performed
injection work, the main qualitative source of exposure, days with injection was obtained only
in four categories, making the exposure characterisation even cruder. However, this was the
best we could perform under the given circumstances.
The main reason for the use of the NMA-based grout, was its low toxicity compared to
acrylamide.  An important question is, therefore, to what degree the workers were also exposed
to pure acrylamide monomer during the grouting operations. According to information
provided by the producer and the Swedish analyses of Solution 1 used in Hallandsåsen,
acrylamide concentrations were between 2.5-5.4%.
However, the actual content of acrylamide in the NMA grout during unfavourable conditions in
tunnel work is very unclear, partly because of  protracted polymerisation of the grout in the
cold tunnel, and partly due to the reversibility of the reaction, where NMA is hydrolysed back
to acrylamide. Under favourable conditions, the polymerisation should be completed after 6-12
hours.  Polymerisation experiments have shown delayed polymerisation of up to one week after
the mixing of the components (Ødegård and Ringstad, 1999).   The observation of very high
acrylamide concentrations (90.6 mg/L) as late as 5 months after the injection work,
demonstrates how uncertain the degree of exposure to pure acrylamide was in these workers.
Measurements in the tunnel water after the cessation of the injection work indicated a 2:1 ratio
of the concentration of NMA to acrylamide, compared with 5-10:1 in the grout. Thus, exposure
to the mixed, but not yet polymerised product may have led to higher concentrations of
acrylamide than previously believed. Still, there is insufficient information available on how
these substances actually interact.
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In conclusion, the 25 workers seem to have been relevantly exposed to NMA and acrylamide
monomer during injection work from 8 to 24 months, with potential, but most probably limited
exposure from the tunnel water after the grouting injection had come to a halt. The Hb adduct
levels in subjects with the most recently taken blood samples indicate elevated levels, but these
are definitely lower than those that have been reported in the workers in the Swedish tunnel
project. Based on the task performed, and indications from the Swedish study (Hagmar et al.,
2001), it is assumed that the most important route of exposure has been through the skin.
The knowledge on which doses of acrylamide that are necessary for development of clinical
nervous system effects in humans is limited.  However, a «no observed adverse effect level»
(NOAEL) related to Hb adduct levels in the range of 0.3-1.0 nmol has been reported for short
time exposure (Törnqvist et al., 1998). Although great uncertainties exist, only 3 subjects in the
present study among those 11 subjects with blood samples taken less than 70 days after
cessation of injection work, seem to have had adduct levels above the lower level of this range.
4.4.3  Health effects
The outcome measures of the present study were partly subjective, based on information from
repeated questionnaires, and partly objective, based on measuring a wide range of
neurophysiological parameters. Glutathion S transferase genotypes M and T and cytogenetic
outcomes were measured in blood samples.
4.4.3.1  Subjective symptoms
With regard to the subjective reports of symptoms, we could not make valid comparisons
between the index and the reference group, as the questions were formulated slightly
differently in the two groups, and were not related to the same periods of time.  However, when
assessing the potential reversibility of symptoms in the index group, the prevalence was in
general higher at the first examination 4 months post exposure compared to the examination
one year later. No statistically significant differences were observed, however, neither for
symptoms related to the peripheral nor to the autonomous nervous system.  Of symptoms in the
CNS,  nausea and/or dizziness was significantly reduced after one year.  Also for symptoms in
the upper airways and in the skin, the prevalence was higher at the first examination compared
to one year later. Peeling of skin, a typical sign related to acrylamide exposure, was reported by
34.8% 4 months post exposure, compared to 16.7% one year later. Eczema and skin irritation
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was also significantly reduced after one year.  These results indicate some reversibility of
symptoms which are most probably related to NMA/acrylamide exposure.  However, exposure
to other airway and irritants during the actual period 4 months post exposure, compared to the
work performed one year later may also have contributed to some of the observed differences.
In addition, one cannot completely exclude that the massive media focus and anxiety in the
workers during the immediate period post exposure may have influenced on the reported
symptom prevalence.
4.4.3.2  Neurophysiological measurements
Previous reports on acrylamide effects in man have mainly been related to the primary production of
acrylamide from acrylonitrile or to the polymerisation of acrylamide to polyacrylamide (WHO 1985).
Later, similar effects were reported in tunnel workers related to grouting operations (Graveleau 1970,
Kesson 1977, Mapp 1977). In most cases, the symptoms and signs have been shown to be reversible,
with full restitution 2-12 months after the cessation of exposure (WHO 1985, Garland 1967, Tilson
1981). However, symptoms have persisted for several years in severe intoxications (Kesson 1977,
Myers 1991).The grouts used by the workers in the aforementioned studies seem mainly to have been
based on pure acrylamide, or in one study on N-Methylacrylamide and Methylen-bis-acrylamide
(Graveleau et al 1970). Thus, the Swedish study (Hagmar et al 2001) and the present study are, to our
knowledge, the first to report neurological effects in workers exposed to grouts based on N-
methylolacrylamide.
Animal studies and previous clinical studies of acrylamide neurotoxicity have shown an  axonal  lesion
of the distal “dying back “ type, which is typical for several neurotoxic substances (Tilson, 1981,
Smith and Oehme 1991). An axonal lesion is characterised by the reduction of motor and/or sensory
amplitudes. The mechanism causing this effect is not completely understood, but a direct neurotoxic
effect at the nerve endings where the “blood-nerve-barrier” is weak, or a toxic effect on neuronal
metabolism and protein synthesis have been suggested as possible explanations.  Previous studies have
indicated that acrylamide both affects motor and sensory nerve fibres, where long, sensory fibres seem
to be the most vulnerable (Smith and Oehme, 1991).
Most neurographical measurements in this study showed no significant differences in the mean
results, neither when compared to the reference group nor over time. There was, however, a
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slight, but significant reversible effect in mean sensory nerve conduction and motor distal delay
in the ulnar nerve and also a reduction of mean sensory nerve conduction and mean sensory
amplitude in the sural nerve on examination after 16 months. By using a set of exposure
variables, exposure-related improvements were observed both in the median nerve (motor and
sensory NCV and F-response) and the ulnar nerve (sensory NCV, F-response), which indicates
a reversible neurotoxic effect, although small and possibly subclinical.
The findings in the upper limbs showed reductions of conduction velocities, which indicates a
toxic effect on myelin, and only a slightly significant reduction in sensory amplitude in the
median nerve. This finding is in contrast to previous studies (Fullerton 1969, He et al 1989,
Takahashi et al.1971) on acrylamide exposure, which have rather consistently shown reduced
amplitudes as a sign of axonal degeneration. Considering the large random variation in the
amplitude measurements, the intermittent NMA/acrylamide exposure over a relatively long
time (two years) may not have been sufficient for detecting any effect on the amplitudes in such
a small group of workers 4 months or more after the cessation of exposure.
 The early, reversible changes were found in the upper and not in the lower extremities, which
is uncharacteristic for polyneuropathies.  A possible explanation may be that the effect could be
caused by direct contact after diffusion through the skin.  This may possibly cause a direct,
myelinolytic effect on distal nerve fibres which is different from the toxic effect on neuron
metabolism causing axonal damage found in other studies of acrylamide. However, somewhat
surprisingly, there was an apparent  reduction in mean sensory nerve conduction and  mean
sensory amplitude in the sural nerve from four to 16 months post exposure. The type and
localisation of this lesion is more in accordance with previous reports of acrylamide
neurotoxicity. The delayed findings, if not a random error, could indicate that the changes may
have taken a longer time to develop and have persisted for a longer time than one would
expect.
All the time-related exposure indices (tunnel time, injection time, exposure time index and
(injection time x intensity index)) were highly correlated to improvements in NCV. Few group
differences were observed in the outcome parameters at the group level.  Thus, these results
illustrate that qualitative data can be optimised to create relevant exposure contrasts, and give
results which otherwise could have been overlooked. Another point is that the more
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sophisticated weighted or combined indices gave no better prediction of the outcomes than
injection time (no. of days with injection work). The intensity index, based on frequency of
tasks was not at all a good predictor of any reversibility outcome.
4.4.3.3  Effects on the visual system
The results from the visual evoked response (VEP) measurements did not differ significantly
between the exposed group and the reference group. However, a non-significant prolongation
of mean P 100 was observed. One worker in the present study reported visual disturbances
during ongoing exposure, with great problems with reading.  His visual evoked response was
pathological with prolonged latency suggesting demyelination at the first examination, and was
normalized after one year. This may have been be a neurotoxic effect of acrylamide, but other
pathological mechanisms, for instance retrobulbar neuritis of other origin cannot be excluded.
In animal studies, acrylamide has been shown to affect the visual system (Schaumberg and
Spencer 1979, Canavagh 1982, Merigen et al 1985, Eskin et al 1985), including visual evoked
response abnormalities (Boyes et al 1980). ).  Human case histories have also reported visual
effects (Mapp et al 1977, Myers et al 1991).
Electroretinography (ERG) with  stimulation frequency 30 Hz showed significantly reduced
amplitudes among the exposed, compared to the reference group. With photopic stimulation the
function of the cones located in the fovea and central parts of the retina is tested. Rapid, 30 Hz
stimulation is more sensitive to slight changes than stimulation with 2hz frequency. Our
findings indicate a slight lesion of the cone photoreceptors. The cones are necessary for colour
vision and sharp vision of details.
To study the function of the rod photoreceptors 20 minutes of darkness adaptation is necessary
before scotopic stimulation. The rods are located in the periphery of the retina and responsible
for night vision. Scotopic stimulation with darkness adaptation was not performed in our study
but will be of interest in later supplementary studies.
In another study of tunnel workers with past exposure to NMA grout, we have indications of
possible irreversible effects on colour vision in the blue green area and also slight effects on the
vision field (Goffeng et al., 2000, Goffeng et al., 2002, in preparation).
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4.4.3.4  Effects on the autonomous nervous system
We did not perform any tests with a specific focus on autonomous nerve functions. No clear
differences were observed between the groups from the symptom questionnaire (table 7).
However, one of the workers reported acute problems with voiding and signs of urinary
retention during an extreme period of injection work.
4.4.3.5 Examination of glutathion S transferase genotypes
About 50% of the population lack GSTM1 activity and 15% has very low GSTT1 activity due
to genetic defects. These individuals might in theory have increased risk for injuries caused by
acrylamide. Since many GSTs are potentially involved in the detoxification, there is only a
weak effect if one of them is lacking. Therefore, lager study groups may be necessary to
demonstrate increased susceptibility associated with a particular genotype. Furthermore, the
kinetic parameters of different GSTs are not sufficient to evaluate their importance in vivo,
since the relative expression level in the target cells which is an important determinant, still is
an unknown factor. The interpretation of the data analysed in relation to GST genotypes should
therefore be done with care. The most consistent finding here is the effect of GSTM1 and T1
genotypes on the number of chromatid gaps in acrylamide exposed workers (Table 26, 27,and
28). These data may indicate that individuals with intact genes (active enzymes) are less prone
to such chromosomal aberrations when exposed to acrylamide.
4.4.3.6  Examination of genotoxic effects.
Measurements of hemoglobin adducts of acrylamide will give an indication of the exposure of
the subjects under study, but information on the biological effects of exposure cannot be
obtained with this method.  A direct measure of damage to the cells after exposure can be
obtained by chromosome studies.  An association between a high amount of chromosome
damage in lymphocytes and cancer has been shown (Hagmar et al., 1994), indicating the
relevance of the method for possible health effects.  Lymphocyte populations in humans seem
to have a longer life-span than previously considered  (Gundy et al., 1992; Bogen, 1993),
which gives the possibility of scoring effects of recent, but not prevailing, exposure. In addition
the metabolite compound, glycidamide, is a relatively stable epoxid with long half-life in vivo,
evenly distributed in tissues of animals (Dearfield et al.1995). Some studies have suggested
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that this metabolite is the active chromosome damaging agent. These arguments were the
background for studying chromosomal aberrations in the Rhoca-Gil exposed workers. In
previous studies any relevance to possible health effects is shown only for the increased
frequencies of number of cells with aberrations including chromatid and chromosome breaks.
In the present study no significant differences were found between the exposed workers and
their matched controls for most of the comparisons with these three effect parameters. Only for
less exposed workers compared to their matched controls (table 24) was there a significant
difference in the number of cells with aberrations. The median value for this parameter was 3
for the exposed group  compared to 2 for controls indicating that more exposed workers were
in the higher range.  However, the three subjects with clearly elevated adduct levels, did not
have higher levels of chromosome aberations than the remaining of the exposed subjects.
When grouping the participants according to genotype, the numbers decreased drastically and it
would thus be difficult to demonstrate any significant differences.  But for the exposed workers
with GSTM1-/GSTT1- a trend was indicated with higher frequencies for all effect parameters
for the exposed group compared to controls with the same genotype (table 28). It is also of
interest that GSTT1, which in the kinetic study  had the highest affinity for acrylamide (see
4.3.6) was the only genotype which came out as significant for the number of chromatid gaps.
We have also included this parameter since the results are so consistent for all the comparisons
done, and it has recently been recommended that such analyses should be included (Paz-y-
Mino et al., 2002). Although chromatid gaps may be indicative of damage to the DNA, we have
no documentation for a connection between this parameter and possible health effects.
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4.4.4  Preventive measures
How can it happen that a toxic compound that has been studied in depth for decades can still
lead to occupational and environmental effects during construction work both in  Norway and
Sweden, two countries which both have a strong tradition of protecting the health and safety of
workers?  This question has recently been raised elsewhere (Kjuus 2001), but will also be
shortly discussed here.
Both in Hallandsåsen and Romeriksporten tunnel projects the water leakage became
unexpectedly high due to the extremely unstable rock structures in the tunnel area.  In the
Norwegian project, several of the small lakes in the area were almost emptied during the
construction work. These environmental problems, with the potential disturbance of the ground
water level, came in addition to the possible health risk to the workers. It is believed that some
of these unexpected problems could have been avoided if the projects had been planned better.
Thus, one may also ask if large construction projects of this type are subject to so tight time
limits owing to time pressure that crucial stages both in the planning and implementation of the
project may suffer, and that this has direct implications for the workers. For example, the
traditional grouting technique with cement is time-consuming.  It is easy to use more of the
«fast» grouting agents, such as those based on acrylamide when pressed for time.  When
grouting agents are used in tunnel projects the common practice has been that they are injected
into the rock before blasting, thus preventing water leakage. However, due to the unexpected
water leakages and the pressure on the time schedule for completing the tunnel work, the grouts
were also injected into fissures that leaked water after blasting.  Thus, the normal
polymerisation of the gel was incomplete and was disturbed by the water leakage. As the
injection work often lasted until the leakage was under control, this could lead to very long
working hours. Some Norwegian workers reported continuous work of up to 24 hours in order
to finish a job. One would believe that less NMA grout could have been used under a different
time schedule.
As the predominant uptake of NMA from the grout is believed to be by the dermal route,
another challenge in this kind of injection work is to prevent skin contact with the grouting
agent.  The lack of proper information to the workers in Romeriksporten due to incomplete
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material safety data sheets may have led to less regular use of personal protection devices than
otherwise would have been used.  Stricter routines were introduced when this was revealed.
However, all 25 workers reported having used gloves during injection work, and the majority
used rain jackets and trousers. Still, 80% reported skin contact with the grouting agent, and all
reported skin contact with contaminated tunnel water and that they were «completely wet»
from tunnel water. Correspondingly, Hagmar et al. report that none of the workers had used
appropriate personal protection devices (Hagmar et al., 2001).  By conducting hand rinses on
the workers and analysing the rinse water, other studies have also shown that nearly all the
grouters had hands contaminated with acrylamide despite wearing of gloves (Hills et al., 1986,
McHugh 1987).  It was not determined whether the acrylamide contamination was due to
wearing gloves over previously contaminated hands or due to permeation of acrylamide
through the glove material. Thus, even when proper protection with gloves and rain jackets is
worn, it is still difficult to avoid skin contact with the grout. One solution to this problem
would be to substitute the NMA grout with a less toxic agent. When the use of NMA-based
grout was stopped in August 1997, one of the alternative grouts that were used contained
isocyanates.  Thus, the choice between alternative substitutes is not easy.
4.5.  Conclusion
In  25 tunnel workers exposed to acrylamide and N-methylol acrylamide during grouting work
in Romeriksporten in the period 1995-1998 who were examined 4 and 16 months after the
cessation of the injection work, and compared to 50 unexposed tunnel workers, the main
findings were the following:
- Slightly more symptoms related to the nervous system were observed in the exposed subjects
during grouting injection work, compared to one year later.
- Sensory nerve conduction velocity and distal delay in the ulnar nerve were reduced/prolonged
compared to the referents, with normalisation after one year.
When reversibility was further examined, exposure-related improvements were observed, both
in the median nerve (motor and sensory NCV and F-response, motor amplitude) ulnar nerve
(sensory NCV, F-response) and tibial nerve (motor amplitude). The findings were more marked
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in the upper than in the lower extremities with signs of demyelination being more prominent
than axonal changes.
- A slight reduction of mean sensory nerve conduction and mean sensory amplitude in the
sural nerve was observed after 16 months, which may indicate a protracted axonal effect
 - Examinations of visual evoked reponse and electroretinography 16 months post exposure
indicated slight effects on the visual system with significant reduction in the cone
photoreceptor function of the retina, responsible for colour vision and sharpness of  vision.
- There were no clear differences in the neurophysiological measurements related to
polyporphism in the Glutathion-S-transferase genotypes M and T.
- Chromosome studies showed that exposure status and genotype GSTT1- came out as
significant for the number of chromatid gaps.
Thus, the results indicate slight effects on the peripheral nervous system in tunnel workers related to
exposure to N-methylolacrylamide and acrylamide during grouting operations. The effects seemed
largely to have been reversible, with normalisation 16 months post exposure. A possible slight effect
on the visual system, and also a possible slight genotoxic effect require further attention.  To date,
these findings are without any known clinical relevance.  Subjects lacking GST-M1 and GST-T1
seemed to have the highest number of chromatid gaps, indicating that individual susceptibility related
to detoxification of acrylamide and N-metylolacrylamide may have played a role in the observed
effect.  However, in this study of so many outcomes, random associations due to multiple comparisons
may have occurred, and these may have complicated the interpretation of possible effects.
Based on these results, we recommend that exposure to NMA-based grouting agents should be
avoided. At present, this is an unnecessary statement, as the use of  NMA-based grout was banned in
Norway in 2000, owing to the combined experiences from Hallandsåsen and Romeriksporten. Tunnel
workers performing grouting work in the future, however, will also need close follow-up, as several of
the substitutes for NMA-based grouts also may have adverse health effects.
This study has been financed by grants from the Norwegian Confederation of Business and
Industry Work Environmental Fund, Scandinavian Rock Group ANS (SRG), Gardermobanen
AS and  Rhodia PPMC.
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